Publications

Journals

• Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ; on behalf of the IES Steering Committee. (19 Jan 2012). Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. DOI.
• Mallarkey G; Coombes RC. (Jan 2012). Latest advances in the medical treatment of cancer: a 2011 snapshot. Ther Adv Med Oncol. 4:3-8. DOI.
• Payne RE; Hava NL; Page K; Blighe K; Ward B; Slade M; Brown J; Guttery DS; et alZaidi SA; Stebbing J; Jacob J; Yagüe E; Shaw JA; Coombes RC. (17 Jan 2012). The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br J Cancer. 106:375-382. DOI.
• Shaw JA; Page K; Blighe K; Hava N; Guttery D; Ward B; Brown J; Ruangpratheep C; et alStebbing J; Payne R; Palmieri C; Cleator S; Walker RA; Coombes RC. (Feb 2012). Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res. 22:220-231. DOI.
• Mallarkey G; Coombes RC. (Sep 2011). Advancing breast cancer therapy by translational research: highlights of the Improving Care and Knowledge through Translational Research (IMPAKT) breast cancer conference. Ther Adv Med Oncol. 3:223-227. DOI.
• Contractor K; Challapalli A; Barwick T; Winkler M; Hellawell G; Hazell S; Tomasi G; Al-Nahhas A; et alMapelli P; Kenny LM; Tadrous P; Coombes RC; Aboagye EO; Mangar S. (15 Dec 2011). Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res. 17:7673-7683. DOI.
• Contractor KB; Kenny LM; Stebbing J; Rosso L; Ahmad R; Jacob J; Challapalli A; Turkheimer F; et alAl-Nahhas A; Sharma R; Coombes RC; Aboagye EO. (15 Dec 2011). [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res. 17:7664-7672. DOI.
• Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; et alAndersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC. (21 Nov 2011). Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. J Clin Oncol. DOI.
• Palmieri C; Januszewski A; Stanway S; Coombes RC. (Sep 2011). Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer (vol 11, pg 179, 2011). EXPERT REV ANTICANC. 11:1472-1472.
• Dowsett M; Nielsen TO; A'Hern R; Bartlett J; Coombes RC; Cuzick J; Ellis M; Henry NL; et alHugh JC; Lively T; McShane L; Paik S; Penault-Llorca F; Prudkin L; Regan M; Salter J; Sotiriou C; Smith IE; Viale G; Zujewski JA; Hayes DF; International Ki-67 in Breast Cancer Working Group. (16 Nov 2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 103:1656-1664. DOI.
• Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; et alTubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MWK; Reise JA; Wilkinson K; Hupperets P. (20 Aug 2011). Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer. J CLIN ONCOL. 29:3247-3254. DOI.
• Berry DA; Ueno NT; Johnson MM; Lei XD; Caputo J; Rodenhuis S; Peters WP; Leonard RC; et alBarlow WE; Tallman MS; Bergh J; Nitz UA; Gianni AM; Basser RL; Zander AR; Coombes RC; Roche H; Tokuda Y; de Vries EGE; Hortobagyi GN; Crown JP; Pedrazzoli P; Bregni M; Demirer T. (20 Aug 2011). High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. J CLIN ONCOL. 29:3214-3223. DOI.
• Stebbing J; Thiyagarajan A; Surendrakumar V; Payne R; Krell J; Szydlo R; Peston D; Lewis JS; et alCoombes RC; Shousha S. (Sep 2011). Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. J CLIN PATHOL. 64:829-831. DOI.
• Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; et alHogben K; De Nguyen Q; Coombes RC; Aboagye EO. (Nov 2011). Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography. Nucl Med Commun. 32:997-1004. DOI.
• Coombes RC. (Jul 2009). Editorial. Ther Adv Med Oncol. 1:3. DOI.
• Stebbing J; Sharma A; North B; Athersuch TJ; Zebrowski A; Pchejetski D; Coombes RC; Nicholson JK; et alKeun HC. (4 Aug 2011). A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. DOI.
• Berry DA; Ueno NT; Johnson MM; Lei X; Caputo J; Rodenhuis S; Peters WP; Leonard RC; et alBarlow WE; Tallman MS; Bergh J; Nitz UA; Gianni AM; Basser RL; Zander AR; Coombes RC; Roché H; Tokuda Y; de Vries EG; Hortobagyi GN; Crown JP; Pedrazzoli P; Bregni M; Demirer T. (20 Aug 2011). High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 29:3214-3223. DOI.
• Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; et alTubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P. (20 Aug 2011). Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 29:3247-3254. DOI.
• Horimoto Y; Hartman J; Millour J; Pollock S; Olmos Y; Ho KK; Coombes RC; Poutanen M; et alMäkelä SI; El-Bahrawy M; Speirs V; Lam EW. (Sep 2011). ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am J Pathol. 179:1148-1156. DOI.
• Mallarkey G; Coombes RC. (Jan 2011). Latest advances in medical oncology: highlights from Milan ESMO 2010 annual congress. Ther Adv Med Oncol. 3:3-9. DOI.
• Coombes RC; Mallarkey G. (Nov 2010). Latest therapeutic advances from the ASCO 2010 Annual Meeting. Ther Adv Med Oncol. 2:347-350. DOI.
• Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; et alAl-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L. (Jul 2011). Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth. Breast Cancer Res Treat. 128:357-368. DOI.
• Stebbing J; Filipovic A; Ellis IO; Green AR; D'Silva TR; Lenz HJ; Coombes RC; Wang T; et alLee SC; Giamas G. (14 Jun 2011). LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat. DOI.
• Patel BH; Mason AM; Patel H; Coombes RC; Ali S; Barrett AG. (5 Aug 2011). Conversion of α-amino acids into bioactive o-aminoalkyl resorcylates and related dihydroxyisoindolinones. J Org Chem. 76:6209-6217. DOI.
• Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; et alFox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S. (Apr 2011). Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer. 11:93-102. DOI.
• Stebbing J; Thiyagarajan A; Surendrakumar V; Payne R; Krell J; Szydlo R; Peston D; Lewis JS; et alCoombes RC; Shousha S. (Sep 2011). Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. J Clin Pathol. 64:829-831. DOI.
• Stanway SJ; Palmieri C; Stanczyk FZ; Folkerd EJ; Dowsett M; Ward R; Coombes RC; Reed MJ; et alPurohit A. (Apr 2011). Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. Anticancer Res. 31:1367-1372.
• Page K; Hava N; Ward B; Brown J; Guttery DS; Ruangpratheep C; Blighe K; Sharma A; et alWalker RA; Coombes RC; Shaw JA. (12 Apr 2011). Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 104:1342-1348. DOI.
• Palmieri C; Januszewski A; Stanway S; Coombes RC. (Feb 2011). Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther. 11:179-183. DOI.
• Shaw JA; Brown J; Coombes RC; Jacob J; Payne R; Lee B; Page K; Hava N; et alStebbing J. (Feb 2011). Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomark Med. 5:87-91. DOI.
• Coombes RC; Kilburn LS. (22 Jan 2011). Time to TEAM: exemestane, or tamoxifen then exemestane?. Lancet. 377:280-281. DOI.
• heathcote D. A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration. Author weblink.
• Toumi M; Barbazanges M; Kroll SHB; Patel H; Ali S; Coombes RC; Barrett AGM. (24 Nov 2010). Concise, flexible syntheses of 4-(4-imidazolyl)pyrimidine cyclin-dependent kinase 2 (CDK2) inhibitors. TETRAHEDRON LETT. 51:6126-6128. DOI.
• Ali S; Buluwela L; Coombes RC. (18 Feb 2011). Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med. 62:217-232. DOI.
• Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; et alScheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S. (23 Dec 2010). A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. J Med Chem. 53:8508-8522. DOI.
• Sharma A; Ngan S; Nandoskar A; Lowdell C; Lewis JS; Hogben K; Coombes RC; Stebbing J. (Oct 2010). Schizophrenia does not adversely affect the treatment of women with breast cancer: a cohort study. Breast. 19:410-412. DOI.
• Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Bliss JM; et alCoombes RC; Kilburn LS. (Nov 2010). Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat. 124:153-161. DOI.
• Kenny LM; Contractor KB; Hinz R; Stebbing J; Palmieri C; Jiang J; Shousha S; Al-Nahhas A; et alCoombes RC; Aboagye EO. (15 Aug 2010). Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res. 16:4236-4245. DOI.
• Thiruchelvam PT; Lai CF; Hua H; Thomas RS; Hurtado A; Hudson W; Bayly AR; Kyle FJ; et alPeriyasamy M; Photiou A; Spivey AC; Ortlund EA; Whitby RJ; Carroll JS; Coombes RC; Buluwela L; Ali S. (Jun 2011). The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat. 127:385-396. DOI.
• Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; et alLiu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ. (20 Jul 2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 28:3422-3428. DOI.
• Gojis O; Rudraraju B; Gudi M; Hogben K; Sousha S; Coombes RC; Cleator S; Palmieri C. (Feb 2010). The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol. 7:83-89. DOI.
• Jiao LR; Szydlo R; Habib NA; Coombes RC; Stebbing J. (3 May 2010). Reply to Z.S. Lalmahomed et al. J Clin Oncol. DOI.
• Peck B; Chen CY; Ho KK; Di Fruscia P; Myatt SS; Coombes RC; Fuchter MJ; Hsiao CD; et alLam EW. (Apr 2010). SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 9:844-855. DOI.
• Filipović A; Gronau JH; Green AR; Wang J; Vallath S; Shao D; Rasul S; Ellis IO; et alYagüe E; Sturge J; Coombes RC. (Jan 2011). Biological and clinical implications of nicastrin expression in invasive breast cancer. Breast Cancer Res Treat. 125:43-53. DOI.
• Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; et alMedema RH; Hartman J; Lykkesfeldt AE; Lam EW. (20 May 2010). FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 29:2983-2995. DOI.
• Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW. (Jan 2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 8:24-34. DOI.
• Gray KR; Contractor KB; Kenny LM; Al-Nahhas A; Shousha S; Stebbing J; Wasan HS; Coombes RC; et alAboagye EO; Turkheimer FE; Rosso L. (7 Feb 2010). Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol. 55:695-709. DOI.
• Keun HC; Sidhu J; Pchejetski D; Lewis JS; Marconell H; Patterson M; Bloom SR; Amber V; et alCoombes RC; Stebbing J. (1 Nov 2009). Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy. CLIN CANCER RES. 15:6716-6723. DOI.
• Kenny LM; Contractor KB; Stebbing J; Ai-Nahhas A; Palmieri C; Shousha S; Coombes RC; Aboagye EO. (1 Nov 2009). Altered Tissue 3 '-Deoxy-3 '-[F-18]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography. CLIN CANCER RES. 15:6649-6657. DOI.
• Jiao LR; Apostolopoulos C; Jacob J; Szydlo R; Johnson N; Tsim N; Habib NA; Coombes RC; et alStebbing J. (20 Dec 2009). Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol. 27:6160-6165. DOI.
• Castellano L; Giamas G; Jacob J; Coombes RC; Lucchesi W; Thiruchelvam P; Barton G; Jiao LR; et alWait R; Waxman J; Hannon GJ; Stebbing J. (15 Sep 2009). The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. P NATL ACAD SCI USA. 106:15732-15737. DOI.
• Tuthill M; Pell R; Guiliani R; Lim A; Gudi M; Contractor KB; Lewis JS; Coombes RC; et alStebbing J. (Aug 2009). Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis. EUR J CANCER. 45:2146-2149. DOI.
• Bertelli G; Hall E; Ireland E; Snowdon CF; Jassem J; Drosik K; Karnicka-Mlodkowska H; Coombes RC; et alBliss JM. (Mar 2010). Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol. 21:498-505. DOI.
• Wortham NC; Ahamed E; Nicol SM; Thomas RS; Periyasamy M; Jiang J; Ochocka AM; Shousha S; et alHuson L; Bray SE; Coombes RC; Ali S; Fuller-Pace FV. (19 Nov 2009). The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene. 28:4053-4064. DOI.
• Contractor KB; Kenny LM; Stebbing J; Al-Nahhas A; Palmieri C; Sinnett D; Lewis JS; Hogben K; et alOsman S; Shousha S; Lowdell C; Coombes RC; Aboagye EO. (1 Sep 2009). [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 15:5503-5510. DOI.
• Ali S; Heathcote DA; Kroll SHB; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; et alFuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AGM; Coombes RC. (1 Aug 2009). The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity. CANCER RES. 69:6208-6215. DOI.
• Cleator SJ; Ahamed E; Coombes RC; Palmieri C. (Jun 2009). A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 9 Suppl 1:S6-S17. DOI.
• Rasul S; Balasubramanian R; Filipović A; Slade MJ; Yagüe E; Coombes RC. (16 Jun 2009). Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer. 100:1879-1888. DOI.
• Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; et alFilipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW. (Jul 2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol. 35:57-68.
• Horlock C; Stott B; Dyson PJ; Morishita M; Coombes RC; Savage P; Stebbing J. (31 Mar 2009). The effects of trastuzumab on the CD4+CD25+FoxP3+and CD4+IL17A+T-cell axis in patients with breast cancer. BRIT J CANCER. 100:1061-1067. DOI.
• Giamas G; Castellano L; Feng Q; Knippschild U; Jacob J; Thomas RS; Coombes RC; Smith CL; et alJiao LR; Stebbing J. (May 2009). CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions. Nucleic Acids Res. 37:3110-3123. DOI.
• McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; et alPolychronis A; Coombes RC; Lam EW. (Mar 2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 8:582-591. DOI.
• Lee B; Franklin I; Lewis JS; Coombes RC; Leonard R; Gishen P; Stebbing J. (Jun 2009). The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur J Cancer. 45:1597-1602. DOI.
• Payne RE; Yagüe E; Slade MJ; Apostolopoulos C; Jiao LR; Ward B; Coombes RC; Stebbing J. (Jan 2009). Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics. 10:51-57. DOI.
• McParland BJ; Miller MP; Spinks TJ; Kenny LM; Osman S; Khela MK; Aboagye E; Coombes RC; et alHui AM; Cohen PS. (Oct 2008). The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide F-18-AH111585 in Healthy Volunteers. J NUCL MED. 49:1664-1667. DOI.
• Slade MJ; Payne R; Riethdorf S; Ward B; Zaidi SA; Stebbing J; Palmieri C; Sinnett HD; et alKulinskaya E; Pitfield T; McCormack RT; Pantel K; Coombes RC. (13 Jan 2009). Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer. 100:160-166. DOI.
• Mintz PJ; Habib NA; Jones JL; Giamas G; Lewis JS; Bowen RL; Coombes RC; Stebbing J. (15 Sep 2008). The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. CANCER. 113:1489-1495. DOI.
• Palmieri C; Coombes RC; Kim SB; Cleator S. (19 Jul 2008). Ethnicity and breast cancer research. Lancet. 372:188-189. DOI.
• Lee B; Lim A; Lalvani A; Descamps MJ; Leonard R; Nallamala S; Lewis JS; Coombes RC; et alStebbing J. (Dec 2008). The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol. 19:2001-2006. DOI.
• Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW. (Jul 2008). Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther. 7:2022-2032. DOI.
• Kenny LM; Coombes RC; Oulie I; Contractor KB; Miller M; Spinks TJ; McParland B; Cohen PS; et alHui AM; Palmieri C; Osman S; Glaser M; Turton D; At-Nahhas A; Aboagye EO. (Jun 2008). Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand F-18-AH111585 in breast cancer patients. J NUCL MED. 49:879-886. DOI.
• Thomas RS; Sarwar N; Phoenix F; Coombes RC; Ali S. (Mar 2008). Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J MOL ENDOCRINOL. 40:173-184. DOI.
• Come SE; Buzdar AU; Ingle JN; Johnston SRD; Brodie AM; Coombes RC; Miller WR; Pritchard KI; et alWiner EP; Zujewski JA; Goss PE. (1 Feb 2008). Endocrine and Targeted Manipulation of Breast Cancer: Summary statement for the Sixth Cambridge Conference. CANCER. 112:673-678. DOI.
• Krol J; Francis RE; Albergaria A; Sunters A; Polychronis A; Coombes RC; Lam EW. (Dec 2007). The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 6:3169-3179. DOI.
• Buzdar AU; Coombes RC; Goss PE; Winer EP. (1 Feb 2008). Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 112:700-709. DOI.
• Jiang J; Sarwar N; Peston D; Kulinskaya E; Shousha S; Coombes RC; Ali S. (1 Oct 2007). Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res. 13:5769-5776. DOI.
• Coombes RC. (1998). Aromatase inhibitors and their use in the adjuvant setting. RECENT RES CANCER. 152:277-284.
• Baur M; van Oosterom AT; Diéras V; Tubiana-Hulin M; Coombes RC; Hatschek T; Murawsky M; Klink-Alakl M; et alHudec M; Dittrich C. (Feb 2008). A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 134:125-135. DOI.
• Coombes RC; Kilburn LS; Snowdon CF; Bliss JM; Intergroup Excemestane Study. (12 May 2007). Exemestane tamoxifen? Reply. LANCET. 369:1600-1601.
• Coombes RC; Kilburn LS; Snowdon CF. (17 Mar 2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. (vol 369, pg 559, 2007). LANCET. 369:906-906.
• Cleator S; Heller W; Coombes RC. (Mar 2007). Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8:235-244. DOI.
• Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO. (Sep 2007). Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 34:1339-1347. DOI.
• Deshmukh PH; Schulz-Fademrecht C; Procopiou PA; Vigushin DA; Coombes RC; Barrett AGM. (Jan 2007). Ring-closing metathesis in the synthesis of biologically active peptidomimetics of apicidin A. ADV SYNTH CATAL. 349:175-183. DOI.
• Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; et alDelozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM; Intergroup Exemestane Study. (17 Feb 2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369:559-570. DOI.
• Marson CM; Mahadevan T; Dines J; Sengmany S; Morrell JM; Alao JP; Joel SP; Vigushin DM; et alCoombes RC. (1 Jan 2007). Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. BIOORG MED CHEM LETT. 17:136-141. DOI.
• Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; et alSnowdon CF; Hall E; Bliss JM; Coombes RC; Intergroup Exemestane Study group. (Feb 2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 8:119-127. DOI.
• Slade MJ; Coombes RC. (Jan 2007). The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol. 4:30-41. DOI.
• Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; et alPalmieri C; Coombes RC. (Jan 2007). Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep. 17:253-259.
• Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; et alLove CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC. (15 Nov 2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 12:6737-6747. DOI.
• Hu JC; Booth MJ; Tripuraneni G; Davies D; Zaidi SA; Tamburo de Bella M; Slade MJ; Marley SB; et alGordon MY; Coffin RS; Coombes RC; Kamalati T. (15 Nov 2006). A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow. Clin Cancer Res. 12:6853-6862. DOI.
• Page K; Powles T; Slade MJ; DE Bella MT; Walker RA; Coombes RC; Shaw JA. (Sep 2006). The importance of careful blood processing in isolation of cell-free DNA. Ann N Y Acad Sci. 1075:313-317. DOI.
• Coombes RC. (19 Oct 2006). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004). NEW ENGL J MED. 355:1746-1746.
• Alao JP; Stavropoulou AV; Lam EW; Coombes RC. (2006). Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 5:40. DOI.
• Alao JP; Stavropoulou AV; Lam EWF; Coombes RC; Vigushin DM. (20 Feb 2006). Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. MOL CANCER. 5. DOI.
• Alao JP; Gamble SC; Stavropoulou AV; Pomeranz KM; Lam EWF; Coombes RC; Vigushin DM. (17 Feb 2006). The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. MOL CANCER. 5. DOI.
• Sarwar N; Kim JS; Jiang J; Peston D; Sinnett HD; Madden P; Gee JM; Nicholson RI; et alLykkesfeldt AE; Shousha S; Coombes RC; Ali S. (Sep 2006). Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer. 13:851-861. DOI.
• Madureira PA; Varshochi R; Constantinidou D; Francis RE; Coombes RC; Yao KM; Lam EW. (1 Sep 2006). The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem. 281:25167-25176. DOI.
• Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; et alDobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC. (1 Mar 2006). Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 12:1585-1592. DOI.
• Coombes RC. (28 Jan 2006). David Vigushin - Obituary. BRIT MED J. 332:240-240.
• Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E. (20 Feb 2006). Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 24:910-917. DOI.
• Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Masuda H; Nomura Y; Sakai K; et alSugimachi K; Tominaga T; Uchino J; Yoshida M; Haybittle JL; Davies C; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Forbes JF; Wilcken N; Gnant M; Jakesz R; Ploner M; Yosef HMA; Focan C; Lobelle JP; Peek U; Oates GD; Powell J; Durand M; Mauriac L; Di Leo A; Dolci S; Piccart MJ; Masood MB; Parker D; Price JJ; Hupperets PSGJ; Jackson S; Ragaz J; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Abu-Zahra HT; Portnoj SM; Baum M; Cuzick J; Houghton J; Riley D; Mansel RE; Gordon NH; Davis HL; Beatrice A; Mihura J; Naja A; Lehingue Y; Romestaing P; Dubois JB; Delozier T; Lesec'h JM; Rambert P; Petruzelka L; Pribylova O; Owen JR; Harbeck N; Janicke F; Meisner G; Meier P; Howell A; Ribeiro GC; Swindell R; Burrett J; Clarke M; Collins R; Darby S; Davies C; Elphinstone P; Evans V; Godwin J; Gray R; Harwood C; Hicks C; Jackson D; James S; MacKinnon E; McGale P; McHugh T; Mead G; Morris P; Oulds J; Peto R; Taylor C; Wang Y; Albano J; de Oliveira CF; Gervasio H; Gordilho J; Johansen H; Mouridsen HT; Gelman RS; Harris JR; Henderson IC; Shapiro CL; Christiansen P; Ejlertsen B; Mouridsen HT; Moller S; Overgaard M; Carstensen B; Palshof T; Trampisch HJ; Dalesio O; de Vries EGE; Rodenhuis S; van Tinteren H; Comis RL; Davidson NE; Gray R; Robert N; Sledge G; Tormey DC; Wood W; Cameron D; Chetty U; Forrest P; Jack W; Rossbach J; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Costa A; Veronesi U; Bartelink H; Duchateau L; Legrand C; Sylvester R; Catalano R; Creech RH; Bonneterre J; Fargeot P; Fumoleau P; Kerbrat P; Namer M; Jonat W; Kaufman M; Schumacher M; von Minckwitz G; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schyrver A; Vakaet L; Belfiglio M; Nicolucci A; Pellegrini F; Sacco M; Valentini M; McArdle CS; Smith DC; Galligioni E; Boccardo F; Rubagotti A; Dent DM; Gudgeon CA; Hacking A; Erazo A; Medina JY; Izuo M; Morishita Y; Takei H; Fentiman IS; Hayward JL; Rubens RD; Skilton D; Scheurlen H; Kaufmann M; von Fournier D; Dafni U; Fountzilas G; Klefstrom P; Blomqvist C; Saarto T; Magreiter R; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Le MG; Spielmann M; Bruzzi P; Montanaro E; Rosso R; Sertoli MR; Venturini M; Amadori D; Benraadt J; Kooi M; van de Velde AO; van Dongen JA; Vermorken JB; Castiglione M; Cavalli F; Coates A; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Hall E; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Bonadonna G; Camerini T; De Palo G; Del Vecchio M; Formelli F; Valagussa P; Martoni A; Pannuti F; Cocconi G; Colozza A; Camisa R; Aogi K; Takashima S; Abe O; Ikeda T; Inokuchi K; Kikuchi K; Sawa K; Sonoo H; Korzeniowski S; Skolyszewski J; Ogawa M; Yamashita J; Bonte J; Christiaens R; Paridaens R; Van den Bogaert W; Martin P; Romain S; Hakes T; Hudis CA; Norton L; Wittes R; Giokas G; Kondylis D; Lissaios B; de la Huerta R; Sainz MG; Altemus R; Cowan K; Danforth D; Lichter A; Lippman M; O'Shaughnessy J; Pierce LJ; Steinberg S; Venzon D; Zujewski JA; Paradiso A; De Lena M; Schittulli F; Myles JD; Pater JL; Pritchard KI; Whelan T; Nomura Y; Anderson S; Bass G; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Baum M; Jackson IM; Palmer MK; Ingle JN; Suman VJ; Bengtsson NO; Jonsson H; Larsson LG; Lythgoe JP; Swindell R; Kissin M; Erikstein B; Hannisdal E; Jacobsen AB; Varhaug JE; Erikstein B; Gundersen S; Hauer-Jensen M; Host H; Jacobsen AB; Nissen-Meyer R; Blamey RW; Mitchell AK; Morgan DAL; Robertson JFR; Di Palma M; Mathe G; Misset JL; Clark RM; Levine M; Pritchard KI; Whelan T; Morimoto K; Sawa K; Takatsuka Y; Crossley E; Harris A; Talbot D; Taylor M; Cocconi G; di Blasio B; Ivanov V; Semiglazov V; Brockschmidt J; Cooper MR; Ueo H; Falkson CI; A'Hern R; Ashley S; Powles TJ; Smith IE; Yarnold JR; Gazet JC; Cocoran N; Deshpande N; de Martino L; Douglas P; Hacking A; Host H; Lindtner A; Notter G; Bryant AJS; Ewing GH; Firth LA; Krushen-Kosloski JL; Nissen-Meyer R; Foster L; George WD; Stewart HJ; Stroner P; Malmstrom P; Moller TR; Ryden S; Tengrup I; Tennvall-Nittby L; Carstenssen J; Dufmats M; Hatschek T; Nordenskjold B; Soderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Glas U; Johansson U; Rutqvist LE; Singnomklao T; Wallgren A; Castiglione M; Goldhirsch A; Maibach R; Senn HJ; Thurlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Pritchard KI; Meakin JW; Panzarella T; Pritchard KI; Shan Y; Shao YF; Wang X; Zhao DB; Bahi J; Reid M; Spittle M; Deutsch GP; Senanayake F; Kwong DLW; Bianco AR; Carlomagno C; De Laurentiis M; De Placido S; Buzdar AU; Smith T; Bergh J; Holmberg L; Liljegren G; Nilsson J; Seifert M; Sevelda P; Zielinsky CC; Buchanan RB; Cross M; Royle GT; Dunn JA; Hills RK; Lee M; Morrison JM; Spooner D; Litton A; Chlebowski RT; Caffier H; EBCTC; Oxford CTSU. (Dec 2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. LANCET. 366:2087-2106.
• Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; et alBellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ. (1 Jan 2006). Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res. 12:34-42. DOI.
• Sunters A; Madureira PA; Pomeranz KM; Aubert M; Brosens JJ; Cook SJ; Burgering BM; Coombes RC; et alLam EW. (1 Jan 2006). Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 66:212-220. DOI.
• Raguz S; De Bella MT; Slade MJ; Higgins CF; Coombes RC; Yagüe E. (20 Dec 2005). Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. Int J Cancer. 117:934-941. DOI.
• Coombes RC; Hall E; Gibson LJ. (6 Dec 2005). Exemestane therapy after 2 to 3 years of tamoxifen therapy improved survival compared with 5 years of tamoxifen therapy alone. ANN INTERN MED. 143:824-824.
• Ford HT; Coombes RC; Gazet JC; Gray R; McConkey CC; Sutcliffe R; Quilliam J; Lowndes S. (Mar 2006). Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer. Ann Oncol. 17:401-408. DOI.
• Nitti D; Wils J; Dos Santos JG; Fountzilas G; Conte PF; Sava C; Tres A; Coombes RC; et alCrivellari D; Marchet A; Sanchez E; Bliss JM; Homewood J; Couvreur ML; Hall E; Baron B; Woods E; Emson M; Van Cutsem E; Lise M; EORTC GI Group; ICCG. (Feb 2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 17:262-269. DOI.
• Kenny LM; Vigushin DM; Al-Nahhas A; Osman S; Luthra SK; Shousha S; Coombes RC; Aboagye EO. (1 Nov 2005). Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65:10104-10112. DOI.
• Waterston AM; Gumbrell L; Bratt T; Waller S; Gustav-Aspland J; L'hermenier C; Bellenger K; Campbell M; et alPowles T; Highley M; Bower M; Mouritsen S; Feldmann M; Coombes RC. (Sep 2005). Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother. 54:848-857. DOI.
• Braun S; Vogl FD; Naume B; Janni W; Osborne MP; Coombes RC; Schlimok G; Diel IJ; et alGerber B; Gebauer G; Pierga JY; Marth C; Oruzio D; Wiedswang G; Solomayer EF; Kundt G; Strobl B; Fehm T; Wong GY; Bliss J; Vincent-Salomon A; Pantel K. (25 Aug 2005). A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 353:793-802. DOI.
• Fraser SP; Diss JK; Chioni AM; Mycielska ME; Pan H; Yamaci RF; Pani F; Siwy Z; et alKrasowska M; Grzywna Z; Brackenbury WJ; Theodorou D; Koyutürk M; Kaya H; Battaloglu E; De Bella MT; Slade MJ; Tolhurst R; Palmieri C; Jiang J; Latchman DS; Coombes RC; Djamgoz MB. (1 Aug 2005). Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 11:5381-5389. DOI.
• Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; et alFumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D. (20 Jun 2005). Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 23:4179-4191. DOI.
• Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; et alPeston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC. (Jun 2005). Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 6:383-391. DOI.
• Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Masuda H; Nomura Y; Sakai K; et alSugimachi K; Tominaga T; Uchino J; Yoshida M; Haybittle JL; Davies C; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Forbes JF; Wilcken N; Gnant M; Jakesz R; Ploner M; Yosef HMA; Focan C; Lobelle JP; Peek U; Oates GD; Powell J; Durand M; Mauriac L; Di Leo A; Dolci S; Piccart MJ; Masood MB; Parker D; Price JJ; Hupperets PSGJ; Jackson S; Ragaz J; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Abu-Zahra HT; Portnoj SM; Baum M; Cuzick J; Houghton J; Riley D; Gordon NH; Davis HL; Beatrice A; Mihura J; Naja A; Lehingue Y; Romestaing P; Dubois JB; Delozier T; Mace-Lesec'h J; Rambert P; Andrysek O; Barkmanova J; Owen JR; Meier P; Howell A; Ribeiro GC; Swindell R; Alison R; Boreham J; Clarke M; Collins R; Darby S; Davies C; Elphinstone P; Evans V; Godwin J; Gray R; Harwood C; Hicks C; James S; MacKinnon E; McGale P; McHugh T; Mead G; Peto R; Wang Y; Albano J; de Oliveira CF; Gervasio H; Gordilho J; Johansen H; Mouridsen HT; Gelman RS; Harris JR; Henderson IC; Shapiro CL; Andersen KW; Axelsson CK; Blichert-Toft M; Moller S; Mouridsen HT; Overgaard J; Overgaard M; Rose C; Cartensen B; Palshof T; Trampisch HJ; Dalesio O; de Vries EGE; Rodenhuis S; van Tinteren H; Comis RL; Davidson NE; Gray R; Robert N; Sledge G; Tormey DC; Wood W; Cameron D; Chetty U; Forrest P; Jack W; Rossbach J; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Costa A; Veronesi U; Bartelink H; Duchateau L; Legrand C; Sylvester R; van der Hage JA; van de Velde CJH; Cunningham MP; Catalano R; Creech RH; Bonneterre J; Fargeot P; Fumoleau P; Kerbrat P; Namer M; Jonat W; Kaufmann M; Schumacher M; von Minckwitz G; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schryver A; Vakaet L; Belfiglio M; Nicolucci A; Pellegrini F; Sacco M; Valentini M; McArdle CS; Smith DC; Galligioni E; Boccardo F; Rubagotti A; Dent DM; Gudgeon CA; Hacking A; Erazo A; Medina JY; Izuo M; Morishita Y; Takei H; Fentiman IS; Hayward JL; Rubens RD; Skilton D; Graeff H; Janicke F; Meisner C; Scheurlen H; Kaufmann M; von Fournier D; Dafni U; Fountzilas G; Klefstrom P; Blomqvist C; Saarto T; Margreiter R; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Le MG; Spielmann M; Bruzzi P; Montanaro E; Rosso R; Sertoli MR; Venturini M; Amadori D; Benraadt J; Kooi M; van de Velde AO; van Dongen JA; Vermorken JB; Castiglione M; Cavalli F; Coates A; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Hall E; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Bonadonna G; Camerini T; De Palo G; Del Vecchio M; Formelli F; Valagussa P; Martoni A; Pannuti F; Cocconi G; Colozza A; Camisa R; Aogi K; Takashima S; Abe O; Ikeda T; Inokuchi K; Kikuchi K; Sawa K; Sonoo H; Korzeniowski S; Skolyszewski J; Ogawa M; Yamashita J; Bonte J; Christiaens R; Paridaens R; Van den Boegart W; Martin P; Romain S; Hakes T; Hudis CA; Norton L; Wittes R; Giokas G; Kondylis D; Lissaios B; de la Huerta R; Sainz MG; Altemus R; Cowan K; Danforth D; Lichter A; Lippman M; O'Shaughnessy J; Pierce LJ; Steinberg S; Venzon D; Zujewski J; Paradiso A; De Lena M; Schittulli F; Myles JD; Pater JL; Pritchard KI; Nomura Y; Anderson S; Bass G; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Baum M; Jackson IM; Palmer MK; Ingle JN; Suman VJ; Bengtsson NO; Jonsson H; Larsson LG; Lythgoe JP; Swindell R; Kissin M; Erikstein B; Hannisdal E; Jacobsen AB; Varhaug JE; Erikstein B; Gundersen S; Hauer-Jensen M; Host H; Jacobsen AB; Nissen-Meyer R; Blamey RW; Mitchell AK; Morgan DAL; Robertson JFR; Di Palma M; Mathe G; Misset JL; Clark RM; Levine M; Morimoto K; Sawa K; Takatsuka Y; Crossley E; Harris A; Talbot D; Taylor M; Cocconi G; di Blasio B; Ivanov V; Semiglazov V; Brockschmidt J; Cooper MR; Ueo H; Falkson CI; A'Hern R; Ashley S; Powles TJ; Smith IE; Yarnold JR; Gazet JC; Cocoran N; Deshpande N; di Martino L; Douglas P; Hacking A; Host H; Lindtner A; Notter G; Bryant AJS; Ewing GH; Firth LA; Krushen-Kosloski JL; Nissen-Meyer R; Foster L; George WD; Stewart HJ; Stroner P; Malmstrom P; Moller TR; Ryden S; Tengrup I; Tennvall-Nittby L; Carstenssen J; Dufmats M; Hatschek T; Nordenskjold B; Soderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Glas U; Johansson U; Rutqvist LE; Singnomklao T; Wallgren A; Castiglione M; Goldhirsch A; Maibach R; Senn HJ; Thurlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Pritchard KI; Meakin JW; Panzarella T; Pritchard KI; Shan Y; Shao YF; Wang X; Zhao DB; Boreham J; Chen ZM; Pan HC; Peto R; Bahi J; Reid M; Spittle M; Deutsch GP; Senanayake F; Kwong DLW; Bianco AR; Carlomagno C; De Laurentiis M; De Placido S; Buzdar AU; Smith T; Bergh J; Holmberg L; Liljegren G; Nilsson J; Seifert M; Sevelda P; Zielinsky CC; Buchanan RB; Cross M; Royle GT; Dunn JA; Hills RK; Lee M; Morrison JM; Spooner D; Litton A; Chlebowski RT; Caffier H; EBCTCG. (14 May 2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. LANCET. 365:1687-1717.
• Coombes RC; Howell A; Emson M; Peckitt C; Gallagher C; Bengala C; Tres A; Welch R; et alLawton P; Rubens R; Woods E; Haviland J; Vigushin D; Kanfer E; Bliss JM. (May 2005). High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol. 16:726-734. DOI.
• Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; et alSarwarl N; Heathcote DA; Schwickerath O; Phoenix F; Hill R; Aboagye E; Shousha S; Waxman J; Lemoine NR; Zelent A; Coombes RC; Ali S. (May 2005). Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF (vol 12, pg 452, 2005). GENE THER. 12:862-862. DOI.
• Coombes RC; Bliss JM; Hall E. (1 May 2005). Safety of exemestane in the Intergroup Exemestane Study. J Clin Oncol. 23:3171-3172. DOI.
• Slade MJ; Singh A; Smith BM; Tripuraneni G; Hall E; Peckitt C; Fox S; Graham H; et alLüchtenborg M; Sinnett HD; Cross NC; Coombes RC. (10 Mar 2005). Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer. 114:94-100. DOI.
• Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; et alSarwar N; Heathcote DA; Schwickerath O; Phoenix F; Hill R; Aboagye E; Shousha S; Waxman J; Lemoine NR; Zelent A; Coombes RC; Ali S. (Mar 2005). Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF (vol 12, pg 452, 2005). GENE THER. 12:552-552. DOI.
• Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; et alSarwar N; Heathcote DA; Schwickerath O; Phoenix F; Hill R; Aboagye E; Shousha S; Waxman J; Lemoine NR; Zelent A; Coombes RC; Ali S. (Mar 2005). Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Ther. 12:452-460. DOI.
• Varshochi R; Halim F; Sunters A; Alao JP; Madureira PA; Hart SM; Ali S; Vigushin DM; et alCoombes RC; Lam EW. (4 Feb 2005). ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem. 280:3185-3196. DOI.
• Palmieri C; Coombes RC; Vigushin DM. (2005). Targeted histone deacetylase inhibition for cancer prevention and therapy. Prog Drug Res. 63:147-181.
• Coombes RC. (2 Dec 2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004). NEW ENGL J MED. 351:2461-2461.
• Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; et alCoombes RC; Vigushin DM. (1 Dec 2004). Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res. 10:8094-8104. DOI.
• Sanderson L; Taylor GW; Aboagye EO; Alao JP; Latigo JR; Coombes RC; Vigushin DM. (Oct 2004). Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos. 32:1132-1138. DOI.
• Palmieri C; Saji S; Sakaguchi H; Cheng G; Sunters A; O'Hare MJ; Warner M; Gustafsson JA; et alCoombes RC; Lam EW. (Aug 2004). The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol. 33:35-50.
• Coombes RC; Bliss JM; Hall E. (1 Jul 2004). Adjuvant treatment of breast cancer with exemestane - Reply. NEW ENGL J MED. 351:101-102.
• Neary NM; Small CJ; Wren AM; Lee JL; Druce MR; Palmieri C; Frost GS; Ghatei MA; et alCoombes RC; Bloom SR. (Jun 2004). Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 89:2832-2836. DOI.
• Palmieri C; Vigushin D; Coombes RC. (22 May 2004). Stem-cell therapy for myocardial diseases. Lancet. 363:1734-1735. DOI.
• Marson CM; Serradji N; Rioja AS; Gastaud SP; Alao JP; Coombes RC; Vigushin DM. (17 May 2004). Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 14:2477-2481. DOI.
• Palmieri C; Lam EW; Vigushin D; Coombes RC. (1 May 2004). Value of SERMs in postmenopausal women. Lancet. 363:1477-1478. DOI.
• Raguz S; Tamburo De Bella M; Tripuraneni G; Slade MJ; Higgins CF; Coombes RC; Yagüe E. (15 Apr 2004). Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res. 10:2776-2783.
• Johnston SR; Gumbrell LA; Evans TR; Coleman RE; Smith IE; Twelves CJ; Soukop M; Rea DW; et alEarl HM; Howell A; Jones A; Canney P; Powles TJ; Haynes BP; Nutley B; Grimshaw R; Jarman M; Halbert GW; Brampton M; Haviland J; Dowsett M; Coombes RC; Cancer Research UK Phase I/II Committee. (Apr 2004). A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol. 53:341-348. DOI.
• Palmieri C; Lam EW; Mansi J; MacDonald C; Shousha S; Madden P; Omoto Y; Sunters A; et alWarner M; Gustafsson JA; Coombes RC. (1 Apr 2004). The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res. 10:2421-2428.
• Waterston AM; Salway F; Andreakos E; Butler DM; Feldmann M; Coombes RC. (22 Mar 2004). TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer. 90:1279-1284. DOI.
• Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; et alBertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C; Intergroup Exemestane Study. (11 Mar 2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350:1081-1092. DOI.
• Vigushin DM; Coombes RC. (Mar 2004). Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 4:205-218.
• Vigushin DM; Mirsaidi N; Brooke G; Sun C; Pace P; Inman L; Moody CJ; Coombes RC. (2004). Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol. 21:21-30. DOI.
• Vigushin DM; Dong Y; Inman L; Peyvandi N; Alao JP; Sun C; Ali S; Niesor EJ; et alBentzen CL; Coombes RC. (2004). The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer. Med Oncol. 21:123-131. DOI.
• Sunters A; Fernández de Mattos S; Stahl M; Brosens JJ; Zoumpoulidou G; Saunders CA; Coffer PJ; Medema RH; et alCoombes RC; Lam EW. (12 Dec 2003). FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 278:49795-49805. DOI.
• Singh A; Ali S; Kothari MS; De Bella MT; Smith C; Timms E; Slade MJ; Foxwell BM; et alCoombes RC. (10 Dec 2003). Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: a pilot study. Int J Cancer. 107:700-706. DOI.
• Vigushin DM; Brooke G; Willows D; Coombes RC; Moody CJ. (3 Nov 2003). Pyrazino[1,2-a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I. Bioorg Med Chem Lett. 13:3661-3663.
• Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K. (23 Oct 2003). Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 22:7600-7606. DOI.
• Chen D; Lucey MJ; Phoenix F; Lopez-Garcia J; Hart SM; Losson R; Buluwela L; Coombes RC; et alChambon P; Schär P; Ali S. (3 Oct 2003). T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. J Biol Chem. 278:38586-38592. DOI.
• Palmieri C; Gillmore R; Menzies-Gow A; Fishpool S; Robinson D; Shaw R; Coombes RC. (Oct 2003). Resolution of late-onset asthma following high-dose chemotherapy. Bone Marrow Transplant. 32:847-848. DOI.
• Coombes RC; Gibson L; Hall E; Emson M; Bliss J. (Sep 2003). Aromatase inhibitors as adjuvant therapies in patients with breast cancer. J Steroid Biochem Mol Biol. 86:309-311.
• Singh A; Slade MJ; Coombes RC. (Jun 2003). Letter 1: Bone marrow micrometastasis in breast cancer (Br J Surg 2003; 90: 290-301). Br J Surg. 90:761. DOI.
• Kothari MS; Ali S; Buluwela L; Livni N; Shousha S; Sinnett HD; Vashisht R; Thorpe P; et alVan Noorden S; Coombes RC; Slade MJ. (7 Apr 2003). Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer. 88:1071-1076. DOI.
• Palmieri C; Roberts-Clark D; Assadi-Sabet A; Coope RC; O'Hare M; Sunters A; Hanby A; Slade MJ; et alGomm JJ; Lam EW; Coombes RC. (Apr 2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells. J Endocrinol. 177:65-81.
• Vigushin DM. (Sep 2002). FR-901228 Fujisawa/National Cancer Institute. Curr Opin Investig Drugs. 3:1396-1402.
• Chen D; Washbrook E; Sarwar N; Bates GJ; Pace PE; Thirunuvakkarasu V; Taylor J; Epstein RJ; et alFuller-Pace FV; Egly JM; Coombes RC; Ali S. (25 Jul 2002). Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 21:4921-4931. DOI.
• Singh A; Debella MT; Kothari M; Smith C; Foxwell B; Ali S; Coombes RC. (Jun 2002). A novel functional estrogen receptor assay (FERA). BRIT J SURG. 89:15-15.
• Zammit C; Coope R; Gomm JJ; Shousha S; Johnston CL; Coombes RC. (8 Apr 2002). Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. Br J Cancer. 86:1097-1103. DOI.
• Palmieri C; Cheng GJ; Saji S; Zelada-Hedman M; Wärri A; Weihua Z; Van Noorden S; Wahlstrom T; et alCoombes RC; Warner M; Gustafsson JA. (Mar 2002). Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 9:1-13.
• Fu HL; Moss J; Shore I; Slade MJ; Coombes RC. (Mar 2002). Ultrastructural localization of laminin and type IV collagen in normal human breast. Ultrastruct Pathol. 26:77-80. DOI.
• Ali S; Coombes RC. (Feb 2002). Endocrine-responsive breast cancer and strategies for combating resistance. NAT REV CANCER. 2:101-+. DOI.
• Ali S; Coombes RC. (Feb 2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2:101-112. DOI.
• Marson CM; Rioja AS; Brooke G; Coombes RC; Vigushin DM. (21 Jan 2002). Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase. Bioorg Med Chem Lett. 12:255-259.
• Vigushin DM; Coombes RC. (Jan 2002). Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 13:1-13.
• Agarwal R; Peters TJ; Coombes RC; Vigushin DM. (2002). Tamoxifen-related porphyria cutanea tarda. Med Oncol. 19:121-123. DOI.
• Jensen EV; Cheng G; Palmieri C; Saji S; Mäkelä S; Van Noorden S; Wahlström T; Warner M; et alCoombes RC; Gustafsson JA. (18 Dec 2001). Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A. 98:15197-15202. DOI.
• Ong PJ; Linardou H; Graham HA; Savage P; Hayward CS; Coombes RC; Collins P. (Oct 2001). Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am Heart J. 142:E6. DOI.
• Kothari MS; Tolhurst RS; Yahaya H; Slade MJ; Shousha S; Ali S; Buluwela L; Coombes RC. (Jul 2001). Attenuated oestrogen receptor alpha expression following purification of normal mammary epithelial cells can be restored by adenovirus mediated gene transduction. BRIT J CANCER. 85:45-45.
• Kothari MS; Slade M; Ali S; Sinnett HD; Shousha S; Livni N; Buluwela L; Vashisht R; et alThorpe P; Coombes RC. (Jul 2001). Cultured purified normal breast epithelial cells rapidly lose oestrogen receptor alpha (ER) expression, whereas purified malignant breast cells stably maintain their ER status. BRIT J CANCER. 85:45-45.
• Zammit C; Barnard R; Gomm J; Coope R; Shousha S; Coombes C; Johnston C. (May 2001). Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol. 194:27-34. DOI.
• Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; et alCoombes RC. (May 2001). Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol. 12:685-691.
• Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC. (Apr 2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 7:971-976.
• Thomson SD; Ali S; Pickles L; Taylor J; Pace PE; Lymboura M; Shousha S; Coombes RC. (15 Jan 2001). Analysis of estrogen-responsive finger protein expression in benign and malignant human breast. Int J Cancer. 91:152-158.
• Liu D; Buluwela L; Ali S; Thomson S; Gomm JJ; Coombes RC. (Jan 2001). Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice. Eur J Cancer. 37:268-280.
• Palmieri C; Saji S; Gustafsson JA; Coombes RC. (9 Sep 2000). False negatives in oestrogen-receptor assay. LANCET. 356:944-944.
• Palmieri C; Saji S; Gustafsson JA; Coombes RC. (9 Sep 2000). False negatives in oestrogen-receptor assay. Lancet. 356:944-945. DOI.
• Palmieri C; Fishpool S; Coombes RC. (5 Aug 2000). Tumour markers in malignancies. Two isoforms of oestrogen receptor are now known to exist. BMJ. 321:379-380.
• Chen D; Riedl T; Washbrook E; Pace PE; Coombes RC; Egly JM; Ali S. (Jul 2000). Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell. 6:127-137.
• Ali S; Coombes RC. (Jul 2000). Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia. 5:271-281.
• Smith BM; Slade MJ; English J; Graham H; Lüchtenborg M; Sinnett HD; Cross NC; Coombes RC. (Apr 2000). Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol. 18:1432-1439.
• Shaw JA; Smith BM; Walsh T; Johnson S; Primrose L; Slade MJ; Walker RA; Coombes RC. (Mar 2000). Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res. 6:1119-1124.
• Freue M; Kjaer M; Boni C; Joliver J; Jänicke F; Willemse PH; Coombes RC; Van Belle S; et alPérez-Carrión R; Zieschang J; Ibarra de Palacios P; Rose C. (Feb 2000). Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast. 9:9-16.
• Ong PJL; Linardou H; Graham H; Savage P; Coombes RC; Collins P. (Feb 2000). Tamoxifen is not detrimental to endothelial function in women with breast cancer. J AM COLL CARDIOL. 35:254A-255A.
• Udom DI; Vigushin DM; Linardou H; Graham H; Palmieri C; Coombes RC. (Jan 2000). Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer. 36:177-182.
• Vigushin DM; Ali S; Pace P; Ito K; Adcock I; Coombes RC. (Nov 1999). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. CLIN CANCER RES. 5:3777S-3777S.
• Harper-Wynne C; English J; Meyer L; Bower M; Archer C; Sinnett HD; Lowdell C; Coombes RC. (Sep 1999). Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer. 81:316-322. DOI.
• Mansi JL; Gogas H; Bliss JM; Gazet JC; Berger U; Coombes RC. (17 Jul 1999). Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 354:197-202.
• Wils JA; Bliss JM; Marty M; Coombes G; Fontaine C; Morvan F; Olmos T; Pérez-López FR; et alVassilopoulos P; Woods E; Coombes RC. (Jul 1999). Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 17:1988-1998.
• Dowsett M; Doody D; Miall S; Howes A; English J; Coombes RC. (Jul 1999). Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat. 56:25-34.
• Coombes RC; Harper-Wynne C; Dowsett M. (Jun 1999). Aromatase inhibitors and their use in the sequential setting. Endocr Relat Cancer. 6:259-263.
• Donaldson MJ; Skoumas V; Watson M; Ashworth PA; Ryder H; Moore M; Coombes RC. (Jun 1999). XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 35:1014-1019.
• Harper-Wynne C; Coombes RC. (May 1999). Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer. 35:744-746.
• Slade MJ; Smith BM; Sinnett HD; Cross NC; Coombes RC. (Mar 1999). Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol. 17:870-879.
• Slade MJ; Coope RC; Gomm JJ; Coombes RC. (25 Feb 1999). The human mammary gland basement membrane is integral to the polarity of luminal epithelial cells. Exp Cell Res. 247:267-278. DOI.
• Chen D; Pace PE; Coombes RC; Ali S. (Feb 1999). Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol. 19:1002-1015.
• Marsh SK; Bansal GS; Zammit C; Barnard R; Coope R; Roberts-Clarke D; Gomm JJ; Coombes RC; et alJohnston CL. (28 Jan 1999). Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene. 18:1053-1060. DOI.
• Borgen E; Naume B; Nesland JM; Kvalheim G; Beiske K; Fodstad O; Diel I; Solomayer EF; et alTheocharous P; Coombes RC; Smith BM; Wunder E; Marolleau JP; Garcia J; Pantel K; European ISHAGE Working Grp. (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. CYTOTHERAPY. 1:377-388.
• Abe O; Abe R; Enomoto K; Kikuchi K; Koyama H; Nomura Y; Sakai K; Sugimachi K; et alTominaga T; Uchino J; Yoshida M; Benraadt J; van de Velde AO; van Dongen JA; Vermorken JB; Giokas G; Lissaios B; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Coates A; Forbes JF; Focan C; Lobelle JP; Gates GD; Powell J; Durand M; Mauriac L; Bartholomeus S; Piccart MJ; Gelman RS; Henderson IC; Shapiro CL; Hancock AK; Masood MB; Parker D; Price JJ; Jackson S; Ragaz J; Delozier T; Mace-Lesec'h J; Haybittle JL; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Baum M; Houghton J; Riley D; Dent DM; Gudgeon CA; Hacking A; Gordon NH; Davis HL; Romestaing P; Lehingue Y; Owen JR; Meier P; Howell A; Ribeiro GC; Swindell R; Albano J; de Oliveira CF; Gervasio H; Gordilho J; Carstensen B; Palshof T; Johansen H; Korzeniowski S; Skolyszewski J; Portnoj SM; Andersen KW; Axelsson CK; Blichert-Toft M; Mouridsen HT; Overgaard M; Rose C; Corcoran N; Trampisch HJ; Comis RL; Davidson NE; Gray R; Robert N; Tormey DC; Wood W; Chetty U; Forrest P; Jack W; Rossbach J; Sylvester RJ; van de Velde CJH; Cunningham MP; Bonneterre J; Fumoleau P; Namer M; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; de Schryver A; Belfiglio M; Mari E; Nicolucci A; Scorpiglione N; Yosef HMA; McArdle CS; Smith DC; Lara PC; Boccardo F; Rubagotti A; Erazo A; Medina JY; Izuo M; Morishita Y; Bentley A; Doran Z; Fentiman IS; Hayward JL; Rubens RD; Kaufmann M; Jonat W; Scheurlen H; von Fournier D; Fountzilas G; Klafstrom P; Blomqvist C; Cuzick J; Margreiter R; Castiglione M; Cavilli F; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Pannuti F; Takashima S; Yasutomi T; Sonoo H; Yamashita J; Ogawa M; Welvaart K; Hupperets PSGJ; Bonte J; Tengrup I; Tennvall-Nittby L; Martin P; Romain S; Ingle JN; Suman VJ; Buzdar AU; Smith T; Hakes T; Wittes R; de la Huerta R; Sainz MG; Bonadonna G; del Vecchio M; Valagussa P; Veronesi U; Dubois JB; Bianco AR; Lippman ME; Pierce LJ; Simon R; Steinberg SM; Myles JD; Pater JL; Pritchard KI; Anderson S; Brown A; Bryant J; Costantino J; Dignam J; Fisher B; Redmond C; Wieand S; Wolmark N; Jackson IM; Palmer MK; Bengtsson NO; Larsson LG; Lythgoe JP; Kissin M; Hannisdal E; Varhaug JE; Nissen-Meyer R; Blamey RW; Mitchell AK; Robertson JFR; Ueo H; Mathe G; Misset JL; Abu-Zahra HT; Clarke EA; McLaughlin JR; Clark RM; Levine M; Morimoto K; Sawa K; Takatsuka Y; Gundersen S; Hauer-Jensen M; Host H; Crossley E; Harris A; Beighton A; Clarke M; Collins R; Davies C; Evans V; Godwin J; Greaves E; Harwood C; Jackson D; James S; Lau E; Mead G; Naughten A; Peto R; Tooth A; Rambert P; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Le MG; Spielmann M; Cocconi G; di Blasio B; Catalano R; Creech RH; Brockschmidt J; Cooper MR; Andrysek O; Barkmanova J; Falkson CI; Abraham M; Klijn JGM; Treurniet-Donker AD; van Putten WLJ; Easton D; Powles TJ; Gazet JC; Semiglazov V; Deshpande N; di Martino L; Douglas P; Lindtner A; Notter G; Bryant AJS; Ewing GH; Krushen-Kosloski JL; George WD; Gould A; Stewart HJ; Stroner P; Moller TR; Ryden S; Carstensen J; Hatschek T; Soderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Rutqvist LE; Wallgren A; Holm LE; Thurlimann B; Brenner H; Hercbergs A; Yoshimoto M; DeBoer G; Paterson AHG; Meakin JW; Panzarella T; Naja A; Bahi J; Reid M; Spittle M; Senanayake F; Bergh J; Holmberg L; Sevelda P; Zielinsky CC; Gnant M; Jakesz R; Buchanan RB; Cross M; Dunn JA; Gillespie WM; Kelly K; Morrison JM; Litton A; Chlebowski RT; Bezwoda WR; Caffier H; Early Breast Canc Trialists Collaborative Gr. (19 Sep 1998). Polychemotherapy for early breast cancer: an overview of the randomised trials. LANCET. 352:930-942.
• Taylor J; Lymboura M; Pace PE; A'hern RP; Desai AJ; Shousha S; Coombes RC; Ali S. (21 Aug 1998). An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer. 79:334-342.
• Gulliford T; English J; Colston KW; Menday P; Moller S; Coombes RC. (Jul 1998). A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer. 78:6-13.
• Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC; et alCanc Res Campaign Phase I II Clin Trials C. (Jul 1998). Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. CANCER CHEMOTH PHARM. 42:111-117.
• Archer CD; Lowdell C; Sinnett HD; English J; Khan S; Coombes RC. (May 1998). Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer. 34:816-819.
• Murphy K; Coombes RC; Samson D; Craddock C; Olavarria E; Yong A; Rajan S; Wagner S; et alStern S; Kanfer EJ. (May 1998). Effective mobilisation of peripheral blood stem cells in patients with high-risk primary breast cancer following adjuvant chemotherapy (FEC) and G-CSF. BRIT J HAEMATOL. 101:92-92.
• Fife K; Bower M; Cooper RG; Stewart L; Etheridge CJ; Coombes RC; Buluwela L; Miller AD. (May 1998). Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Ther. 5:614-620. DOI.
• Coombes RC. (Feb 1998). Aromatase inhibitors and their role in the adjuvant treatment strategy. EUR J CANCER. 34:S7-S7.
• Fife K; Buluwela L; Miller A; Coombes RC; Bower M. (1998). Anti-angiogenic gene therapy. BRIT J CANCER. 78:18-18.
• Shaw JA; Smith B; Walsh T; Johnson S; Walker RA; Coombes RC. (1998). Microsatellite alterations in plasma DNA of breast cancer patients. J PATHOL. 186:13A-13A.
• Haynes BP; Grimshaw RM; Griggs LJ; Hardcastle I; Nutley BP; Jarman M; Johnston SRD; Twelves CJR; et alSoukop M; Rea DW; Howell A; Jones A; Coombes RC. (1998). Pharmacokinetios of idoxifene and tamoxifen in a randomised phase II trial in breast cancer patients who have relapsed on tamoxifen. ANN ONCOL. 9:177-177.
• Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC. (1998). Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol. 42:111-117.
• Pace P; Taylor J; Suntharalingam S; Coombes RC; Ali S. (10 Oct 1997). Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem. 272:25832-25838.
• Schoenfeld A; Coombes RC. (Oct 1997). Keratin 19 mRNA is detectable by RT-PCR in lymph nodes of patients without breast cancer - Reply. BRIT J CANCER. 76:1112-1113.
• Gomm JJ; Browne PJ; Coope RC; Bansal GS; Yiangou C; Johnston CL; Mason R; Coombes RC. (10 Jul 1997). A paracrine role for myoepithelial cell-derived FGF2 in the normal human breast. Exp Cell Res. 234:165-173. DOI.
• Schoenfeld A; Kruger KH; Gomm J; Sinnett HD; Gazet JC; Sacks N; Bender HG; Luqmani Y; et alCoombes RC. (May 1997). The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer. 33:854-861.
• Gomm JJ; Coope RC; Browne PJ; Coombes RC. (Apr 1997). Separated human breast epithelial and myoepithelial cells have different growth factor requirements in vitro but can reconstitute normal breast lobuloalveolar structure. J Cell Physiol. 171:11-19. DOI.
• Luqmani YA; Chander SK; Coope RC; Gomm J; Lappi DA; Coombes RC. (Mar 1997). Effect of basic fibroblast growth factor-saporin mitotoxin on breast cancer cell lines in vitro. ONCOL REP. 4:425-428.
• Yiangou C; Cox H; Bansal GS; Coope R; Gomm JJ; Barnard R; Walters J; Groome N; et alShousha S; Coombes RC; Johnston CL. (1997). Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer. Br J Cancer. 76:1419-1427.
• Bansal GS; Cox HC; Marsh S; Gomm JJ; Yiangou C; Luqmani Y; Coombes RC; Johnston CL. (1997). Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer. 75:1567-1574.
• Yiangou C; Gomm JJ; Coope RC; Law M; Luqmani YA; Shousha S; Coombes RC; Johnston CL. (1997). Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer. 75:28-33.
• Pace P; Jarman M; Phillips D; Hewer A; Bliss J; Coombes RC. (1997). Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer. 76:700-704.
• Liu D; Coope RC; Coombes RC; Gomm JJ. (1997). Retroviral infection of FGF2 into breast carcinoma cells. EUR J CELL BIOL. 74:100-100.
• Coope RC; Browne PJ; Yiangou C; Bansal GS; Walters J; Groome N; Shousha S; Johnston CL; et alCoombes RC; Gomm JJ. (1997). The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. Br J Cancer. 75:1621-1630.
• Rees CN; Sinnett D; Lowdell C; English J; Coombes RC. (Dec 1996). A pilot study to evaluate paclitaxel (Taxol) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma. Eur J Cancer. 32A:2354-2356.
• Clarke M; Collins R; Davies C; Godwin J; Gray R; Peto R; Abe O; Abe R; et alEnomoto K; Kikuchi K; Koyama H; Nomura Y; Sakai K; Sugimachi K; Tominaga T; Uchino J; Yoshida M; vandeVelde AO; vanDongen JA; Vermorken JB; Arvelakis A; Giokas G; Lissaios B; Harvey VJ; Holdaway TM; Kay RG; Mason BH; Coates A; Forbes JF; Focan C; Lobelle JP; Peek U; Oates GD; Powell J; Bastert G; Rauschecker H; Sauer R; Sauerbrei W; Schauer A; Schumacher M; Durand M; Mauriac L; Bartholomeus S; Piccart MJ; Gelman RS; Henderson IC; Shapiro CL; Hancock AK; Masood MB; Parker D; Price JJ; Jackson S; Ragaz J; Delozier T; MaceLesech J; Haybittle JL; Cirrincione C; Korzun A; Weiss RB; Wood WC; Baum M; Houghton J; Riley D; Dent DM; Gudgeon CA; Hacking A; Horgan K; Hughes L; Stewart HJ; Gordon NH; Davis HL; Lehingue Y; Owen JR; Meier P; Howell A; Ribeiro GC; Swindell R; Albano J; deOliveira CF; Gervasio H; Gordilho J; Carstensen B; Palshof T; Johansen H; Korzeniowski S; Skolyszewski J; Andersen KW; Axelsson CK; BlichertToft M; Mouridsen HT; Overgaard M; Rose C; Corcoran N; Trampisch HJ; Abeloff MD; Carbone PC; Glick J; Tormey DC; Rossbach J; Scanlon EF; Schurman S; deSchryver A; Yosef HMA; McArdle CS; Smith DC; Lara PC; Boccardo F; Erazo A; Medina JY; Izuo M; Morishita Y; Bentley A; Doran Z; Fentiman IS; Hayward JL; Rubens RD; Kaufmann M; Jonat W; Scheurlen H; vonFournier D; Fountzilas G; Klefstrom P; Blomqvist C; Cuzick J; Margreiter R; Castiglione M; Cavalli F; Collins J; Forbes J; Gelber RD; Goldhirsch A; Lindtner J; Price KN; Rudenstam CM; Senn HJ; Bliss JM; Chilvers CED; Coombes RC; Marty M; Borovik R; Brufman G; Hayat H; Robinson E; Wigler N; Pannuti F; Takashima S; Tasutomi T; Sonoo H; Yamashita J; Ogawa M; Hupperets PSGJ; Bonte J; Tengrup I; TennvallNittby L; Martin P; Romain S; Ahmann D; Schaid DJ; Buzdar AU; Smith T; Hakes T; Norton L; Wittes R; delaHuerta R; Sainz MG; Bonadonna G; delVecchio M; Valagussa P; Veronesi U; Dubois JB; Bianco AR; Lippman ME; Pierce LJ; Simon R; Steinberg SM; Brown A; Fisher B; Redmond C; Wolmark N; Jackson IM; Palmer MK; Ingle JN; Suman VJ; Bengtsson NO; Larsson LG; Lythgoe JP; Kissin M; Hannisdal E; Varhaug JE; NissenMeyer R; Blamey RW; Mitchell AK; Robertson JFR; Nakamura Y; Mathe G; Misset JL; AbuZahra HT; Clarke EA; McLaughlin JR; Clark RM; Levine M; Myles JD; Pater JL; Pritchard KI; Morimoto K; Sawa K; Takatsuka Y; Gundersen S; HauerJensen M; Host A; Crossley E; Durrant K; Harris A; Beighton A; Collins R; Evans V; Greaves E; Harwood C; James S; Lau E; Mead G; Muldal A; Naughton A; Tooth A; Wheatley K; Rambert P; Asselain B; Salmon RJ; Vilcoq JR; Arriagada R; Hill C; Laplanche A; Le MG; Speilmann M; Cocconi G; diBlasio B; Catalano R; Creech RH; Brockschmidt J; Cooper MR; Andrysek O; Barkmanova J; Falkson CJ; Abraham M; Klijn JGM; TreurnietDonker AD; vanPutten WLJ; Easton D; Powles TJ; Gazet JC; Semiglazov V; Deshpande N; diMartino L; Douglas P; Host H; Bryant AJS; Ewing GH; KrushenKosloski JL; Forrest APM; Jack W; McDonald C; Moller TR; Ryden S; Carstensen J; Hatschek T; Soderberg M; Carpenter JT; Albain K; Crowley J; Green S; Martino S; Osborne CK; Ravdin PM; Rutqvist LE; Wallgren A; Holm LE; Yoshimoto M; DeBoer G; Paterson AHG; Meakin JW; Panzarella T; Naja A; Bahi J; Reid M; Spittle M; Senanayake F; Bergh J; Holmberg L; Sevelda P; Zielinsky CC; Jakesz R; Gnant M; Buchanan RB; Cross M; Dunn JA; Gillespie WM; Kelly K; Morrison JM; Litton A; Chlebowski RT; Bezwoda WR; Caffier H. (2 Nov 1996). Ovarian ablation in early breast cancer: Overview of the randomised trials. LANCET. 348:1189-1196.
• Yelland A; Gazet JC; Coombes RC. (Nov 1996). Conservative management of fibroadenoma of the breast. BRIT J SURG. 83:1653-1653.
• Schoenfeld A; Luqmani Y; Sinnett HD; Shousha S; Coombes RC. (Nov 1996). Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer. 74:1639-1642.
• Girling DJ; Thatcher N; Clark PI; Hopwood P; Twiddy S; Stephens RJ; Bailey AJ; Machin D; et alBleehen NM; Bolger JJ; Connolly CK; Hasleton PS; Macbeth FR; Moghissi K; Saunders MI; White RJ; Alcock S; Burt H; Crossley E; Decker E; English J; Foster G; Hannigan K; Heron D; Hutchinson J; Lomax L; Mercer V; Page S; Rothwell T; Staines K; TaylorNeal P; Turnball V; Axford AT; Earl HM; Glaholm J; Falk SJ; Graham JD; Jones DK; Coombes RC; Epstein RJ; Hanham I; Lowdell CP; Newlands E; Smith DB; Cookson JB; Anderson H; Gribbin HR; Sinclair DJM; Carmichael J; Chan SYT; Johnston IDA; Morgan SA; Dunn KS; Manifold IH; Radstone DJ; Lamont A; Robinson ACR; Bissett D; Nicolson MC; Tang OT; Sinnamon DG; Varghese G; Bibby RJ; OReilly JF; Bath JCJ; Bredin CP; Stewart SJ; Whillis D; Wiltshire CR; McIllmurray MB; Bond MG; Wardman AG; Bozzino JM; Ferguson GC; Macmillan CH; Sugden EM; Talbot DC; Quigley IG; Weatherstone RM; Veale D; ORegan PF. (31 Aug 1996). Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. LANCET. 348:563-566.
• Baillie R; Coombes RC; Smith J. (Aug 1996). Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1. Eur J Cancer. 32A:1566-1573.
• Poon GK; Vigushin D; Griggs LJ; Rowlands MG; Coombes RC; Jarman M. (May 1996). Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metab Dispos. 24:565-571.
• Gazet JC; Coombes RC; Ford HT; Griffin M; Corbishley C; Makinde V; Lowndes S; Quilliam J; et alSutcliffe R. (Mar 1996). Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer. 73:758-762.
• Luqmani YA; Bansal GS; Mortimer C; Buluwela L; Coombes RC. (Mar 1996). Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur J Cancer. 32A:518-524.
• Liu QY; Niranjan B; Gomes P; Gomm JJ; Davies D; Coombes RC; Buluwela L. (1 Mar 1996). Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res. 56:1155-1163.
• Bonnefoi HR; Smith IE; Dowsett M; Trunet PF; Houston SJ; da Luz RJ; Rubens RD; Coombes RC; et alPowles TJ. (Feb 1996). Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br J Cancer. 73:539-542.
• Coombes RC; Bliss JM; Wils J; Morvan F; Espie M; Amadori D; Gambrosier P; Richards M; et alAapro M; VillarGrimalt A; McArdle C; PerezLopez FR; Vassilopoulos P; Ferreira EP; Chilvers CED; Coombes G; Woods EM; Marty M. (Jan 1996). Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J CLIN ONCOL. 14:35-45.
• Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; et alAapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M. (Jan 1996). Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol. 14:35-45.
• Mackay AG; OforiKuragu EA; Lansdown A; Coombes RC; Binderup L; Colston KW. (1996). Effects of the synthetic vitamin D analogue EB 1089 and tamoxifen on the growth of experimental rat mammary tumours. ENDOCR-RELAT CANCER. 3:327-335.
• Johnston CL; Cox HC; Gomm JJ; Coombes RC. (22 Dec 1995). Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem. 270:30643-30650.
• Bansal GS; Yiangou C; Coope RC; Gomm JJ; Luqmani YA; Coombes RC; Johnston CL. (Dec 1995). Expression of fibroblast growth factor 1 is lower in breast cancer than in the normal human breast. Br J Cancer. 72:1420-1426.
• ABE O; ABE R; ASAISHI K; ENOMOTO K; HATTORI T; IINO Y; KIKUCHI K; KOYAMA H; et alSAWA K; UCHINO J; YOSHIDA M; VANDEVELDE AO; VERMORKEN JB; FOROGLOU P; GIOKAS G; LISSAIOS B; HARVEY VJ; HOLDAWAY TM; KAY RG; MASON BH; FORBES JF; FOCAN C; LOBELLE JP; PEEK U; OATES GD; POWELL J; BASTERT G; RAUSCHECKER H; SAUER R; SAUERBREI W; SCHAUER A; SCHUMACHER M; GELMAN RS; HENDERSON IC; SHAPIRO CL; HANCOCK AK; JACKSON S; RAGAZ J; DELOZIER T; MACELESECH J; HAYBITTLE JL; CIRRINCIONE C; KORZUN A; WEISS RB; WOOD WC; BAUM M; HOUGHTON J; RILEY D; DENT DM; GUDGEON CA; HACKING A; HORGAN K; HUGHES L; STEWART HJ; GORDON NH; DAVIS HL; OWEN JR; MEIER P; HOWELL A; RIBEIRO GC; SWINDELL R; ALBANO J; DEOLIVEIRA CF; GERVASIO H; GORDILHO J; CARSTENSEN B; PALSHOF T; JOHANSEN H; KORZENIOWSKI S; SKOLYSZEWSKI J; ANDERSEN KW; AXELSSON CK; BLICHERTTOFT M; MOURIDSEN HT; OVERGAARD M; ROSE C; CORCORAN N; TRAMPISCH HJ; ABELOFF MD; CARBONE PC; GLICK J; GRAY R; TORMEY DC; BARTELINK H; FENTIMAN IS; PARIDAENS R; VANDRIEL OJR; SYLVESTER RJ; VANDEVELDE CJH; VANDERSCHUEREN E; VANDONGEN JA; WELVAART K; SCANLON EF; SCHURMAN S; DESCHRYVER A; YOSEF HMA; MCARDLE CS; SMITH DC; LARA PC; BOCCARDO F; IZUO M; MORISHITA Y; BENTLEY A; DORAN Z; HAYWARD JL; RUBENS RD; KAUFMANN M; JONAT W; SCHEURLEN H; VONFOURNIER D; KAUFMANN M; KLEFSTROM P; CUZICK J; MARGREITER R; CAVALLI F; COLLINS J; GELBER RD; GOLDHIRSCH A; ISLEY MR; LINDTNER J; PRICE KN; RUDENSTAM CM; BLISS JM; CHILVERS CED; COOMBES RC; MARTY M; BRUFMAN G; HAYAT H; BOROVIK R; ROBINSON E; PANNUTI F; TAKASHIMA S; YASUTOMI T; SONOO H; YAMASHITA J; OGAWA M; NOMURA Y; BONTE J; TENGRUP I; TENNVALLNITTBY L; MARTIN P; ROMAIN S; AHMANN D; SCHAID DJ; BUZDAR AU; SMITH T; HAKES T; NORTON L; WITTES R; DELAHUERTA R; SAINZ MG; BONADONNA G; DELVECCHIO M; VALAGUSSA P; VERONESI U; DUBOIS JB; BIANCO AR; LIPPMAN ME; PIERCE LJ; SIMON R; STEINBERG SM; BROWN A; FISHER B; REDMOND C; WOLMARK N; JACKSON IM; PALMER MK; INGLE JN; BENGTSSON NO; LARSSON LG; LYTHGOE JP; KISSIN M; HANNISDAL E; VARHAUG JE; BLAMEY RW; MITCHELL AK; ROBERTSON JFR; NAKAMURA Y; MATHE G; MISSET JL; CLARKE EA; MCLAUGHLIN JR; CLARK RM; LEVINE M; MORIMOTO K; GUNDERSEN S; HAUERJENSEN M; HOST H; CROSSLEY E; DURRANT K; HARRIS A; BEIGHTON A; CHADBON D; CLARKE M; COLLINS R; DAVIES C; EVANS V; GODWIN J; GREAVES E; HARWOOD C; JAMES S; MEAD G; MULDAHL A; PETO R; TOOTH A; WHEATLEY K; RAMBERT P; ASSELAIN B; SALMON RJ; VILCOQ JR; ARRIAGADA R; HILL C; LAPLANCHE A; LE MG; SPIELMANN M; COCCONI G; DIBLASIO B; CATALANO R; CREECH RH; BROCKSCHMIDT J; COOPER MR; ANDRYSEK O; BARKMANOVA J; TREURNIETDONKER AD; VANPUTTEN WLJ; EASTON D; POWLES TJ; GAZET JC; SEMIGLAZOV V; DESHPANDE N; DIMARTINO L; DOUGLAS P; LINDTNER A; NOTTER G; NISSENMEYER R; FORREST APM; JACK W; MCDONALD C; MOLLER TR; RYDEN S; CARSTENSEN J; HATSCHEK T; SODERBERG M; CARPENTER JT; ALBAIN K; CROWLEY J; GREEN S; OSBORNE CK; RUTQUIST LE; WALLGREN A; HOLM LE; CASTIGLIONE M; FLUCKIGER H; THURLIMANN B; BRENNER H; HERCBERGS A; YOSHIMOTO M; DEBOER G; PATERSON AHG; PRITCHARD KI; MEAKIN JW; PANZARELLA T; NAJA A; BAHI J; REID M; SPITTLER M; SENANAYAKE F; HOLMBERG L; SEVELDA P; ZIELINSKY CC; JAKESZ R; BUCHANAN RB; CROSS M; DUNN JA; GILLESPIE WM; KELLY K; MORRISON JM; LITTON A; CHLEBOWSKI RT; BEZWODA WR; CAFFIER H. (30 Nov 1995). EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS. NEW ENGL J MED. 333:1444-1455.
• Bonnefoi HR; Smith IE; Dowsett M; Huston SJ; daLuz RJ; Trunet PF; Coombes RC; Rubens RD; et alPowles TJ. (Nov 1995). Therapeutic effects of the aromatase inhibitor fadrozole (F) hydrochloride in advanced breast cancer. EUR J CANCER. 31A:377-377.
• Luqmani YA; Mortimer C; Yiangou C; Johnston CL; Bansal GS; Sinnett D; Law M; Coombes RC. (22 Aug 1995). Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int J Cancer. 64:274-279.
• JAMEEL A; STEIN RC; RAWSON NSB; HEDLEY A; STUTTAFORD J; COOMBES RC. (Jun 1995). COMPARATIVE-STUDY OF INTRAMUSCULAR KETOROLAC TROMETHAMINE AND MORPHINE IN PATIENTS EXPERIENCING CANCER PAIN. INT J ONCOL. 6:1307-1311.
• MORTIMER CJD; LUQMANI Y; SINNETT D; COOMBES RC. (May 1995). MESSENGER-RNA VARIANTS OF FIBROBLAST GROWTH-FACTOR RECEPTOR-TYPE-1 AND RECURRENCE OF BREAST-CANCER. BRIT J SURG. 82:697-698.
• Gomm JJ; Browne PJ; Coope RC; Liu QY; Buluwela L; Coombes RC. (20 Mar 1995). Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads. Anal Biochem. 226:91-99. DOI.
• Johnston CL; Cox HC; Gomm JJ; Coombes RC. (1 Mar 1995). bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. Biochem J. 306 ( Pt 2):609-616.
• JOHNSTON CL; COX HC; GOMM JJ; COOMBES RC. (1 Mar 1995). BFGF AND AFGF INDUCE MEMBRANE RUFFLING IN BREAST-CANCER CELLS BUT NOT IN NORMAL BREAST EPITHELIAL-CELLS - FGFR-4 INVOLVEMENT. BIOCHEM J. 306:609-616.
• STEIN RC; COOMBES RC; GAZET JC; FORD HT; RAWSON NSB. (Mar 1995). GESTRINONE IN MASTALGIA - A RANDOMIZED DOUBLE BIND PLACEBO-CONTROLLED TRIAL - REPLY. BREAST. 4:73-73.
• Coombes RC; Haynes BP; Dowsett M; Quigley M; English J; Judson IR; Griggs LJ; Potter GA; et alMcCague R; Jarman M. (1 Mar 1995). Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res. 55:1070-1074.
• Wils JA; Coombes RC; Bliss JM; Law M; Fountzilas G; Amadori D; AbadEsteve A; Klein HO; et alPintoFerreira E; Reis H; Vassilopoulos P; Tres A; Woods E. (1995). Phase I-II study of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX) at different dose levels in advanced gastric cancer. GI CANCER. 1:55-59.
• Schoenfeld A; Luqmani Y; Smith D; O'Reilly S; Shousha S; Sinnett HD; Coombes RC. (1 Jun 1994). Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 54:2986-2990.
• Gazet JC; Ford HT; Coombes RC; Bland JM; Sutcliffe R; Quilliam J; Lowndes S. (Jun 1994). Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 20:207-214.
• Chander SK; Lansdown AG; Luqmani YA; Gomm JJ; Coope RC; Gould N; Coombes RC. (May 1994). Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours. Br J Cancer. 69:879-882.
• Evans TR; Rowlands MG; Sahota SS; Coombes RC. (Apr 1994). Lack of inhibition of placental estrone sulfatase and aromatase enzymes by vitamin D3 and its analogs. J Steroid Biochem Mol Biol. 48:563-566.
• Evans TR; Rowlands MG; Law M; Coombes RC. (Mar 1994). Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer. 69:555-561.
• Jones AL; Trott P; Cunningham D; Rosin RD; Coleman D; Sauven P; Glazer G; Cunningham D; et alHermon-Taylor J; Coombes RC. (Feb 1994). A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol. 5:123-126.
• Smith J; Yelland A; Baillie R; Coombes RC. (1994). Acidic and basic fibroblast growth factors in human breast tissue. Eur J Cancer. 30A:496-503.
• Dowsett M; Smithers D; Moore J; Trunet PF; Coombes RC; Powles TJ; Rubens R; Smith IE. (1994). Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer. 30A:1453-1458.
• Coombes RC; Chilvers CE; Amadori D; Medi F; Fountzilas G; Rauschecker H; Vassilopoulos P; Ferreira EP; et alVannozzi G; Bliss JM. (Jan 1994). Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol. 5:33-36.
• Dowsett M; Coombes RC. (1994). Second generation aromatase inhibitor--4-hydroxyandrostenedione. Breast Cancer Res Treat. 30:81-87.
• Murray PA; Gomm J; Ricketts D; Powles T; Coombes RC. (1994). The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer. 30A:1218-1222.
• Evans TR; Rowlands MG; Luqmani YA; Chander SK; Coombes RC. (Aug 1993). Detection of breast cancer-associated estrone sulfatase in breast cancer biopsies and cell lines using polymerase chain reaction. J Steroid Biochem Mol Biol. 46:195-201.
• DICKSON IR; ARORA MK; COOMBES RC; SHAO P; EYRE D. (Aug 1993). PYRIDINOLINES AND CROSS-LINKED TYPE-I COLLAGEN N-TELOPEPTIDES AS MARKERS OF BONE METASTASES IN BREAST-CANCER. J BONE MINER RES. 8:S288-S288.
• Shousha S; Luqmani YA; Sannino P; Rio MC; Coombes RC; Theodorou NA. (Jul 1993). pS2 immunostaining of colorectal carcinoma. Mod Pathol. 6:446-448.
• Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC. (19 Jun 1993). Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer. 54:619-623.
• JAMEEL A; LAW M; COOMBES RC; LUQMANI YA. (Jun 1993). SIGNIFICANCE OF HEAT-SHOCK PROTEIN-90 AS A PROGNOSTIC INDICATOR IN BREAST-CANCER. INT J ONCOL. 2:1075-1080.
• Murray PA; Barrett-Lee P; Travers M; Luqmani Y; Powles T; Coombes RC. (Jun 1993). The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer. 67:1408-1412.
• Topham C; Glees J; Coombes RC. (Apr 1993). Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology. 50 Suppl 1:78-80.
• Luqmani YA; Campbell T; Soomro S; Shousha S; Rio MC; Coombes RC. (Apr 1993). Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer. 67:749-753.
• Evans TR; Rowlands MG; Silva MC; Law M; Coombes RC. (Mar 1993). Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol. 44:583-587.
• Evans TR; Stein RC; Pepper JR; Gazet JC; Ford HT; Coombes RC. (1993). A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur J Cancer. 29A:316-319.
• Wils J; Coombes RC; Marty M; Bliss J; Woods E. (1993). Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG). Drugs. 45 Suppl 2:46-50.
• Coombes RC; Jarman M; Dowsett M; Chander SK; Rowlands MG; Di Salle E; Evans TJ. (1993). New endocrine agents for the treatment of breast cancer. Recent Results Cancer Res. 127:267-275.
• Coombes RC. (1993). New targets for cancer therapy. Mol Aspects Med. 14:373-449.
• COOMBES RC. (1993). NEW TARGETS FOR CANCER-THERAPY. MOL ASPECTS MED. 14:373-&.
• Smith J; Chander SK; Baillie R; Coombes RC. (1993). The effect of endocrine therapy on fibroblast growth factor-like activity in nitrosomethylurea-induced rat mammary tumours. Eur J Cancer. 29A:2125-2131.
• Colston KW; Mackay AG; James SY; Binderup L; Chander S; Coombes RC. (15 Dec 1992). EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol. 44:2273-2280.
• Seckl MJ; Rustin GJ; Coombes RC. (Nov 1992). CA-125 is not a useful marker in metastatic breast cancer. Br J Cancer. 66:875-876.
• Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC. (1 Nov 1992). Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 52:5933-5939.
• Jones AL; Powles TJ; Law M; Tidy A; Easton D; Coombes RC; Smith IE; McKinna JA; et alNash A; Ford HT. (Oct 1992). Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol. 10:1547-1552.
• Coombes RC. (Sep 1992). 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer. J Steroid Biochem Mol Biol. 43:145-148.
• Dowsett M; Stein RC; Coombes RC. (Sep 1992). Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol. 43:155-159.
• di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC. (Sep 1992). Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 43:137-143.
• Colston KW; Chander SK; Mackay AG; Coombes RC. (18 Aug 1992). Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 44:693-702.
• Luqmani YA; Graham M; Coombes RC. (Aug 1992). Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer. 66:273-280.
• Davies JH; Dowsett M; Jacobs S; Coombes RC; Hedley A; Shearer RJ. (Jul 1992). Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. Br J Cancer. 66:139-142.
• Wrede D; Luqmani YA; Coombes RC; Vousden KH. (Jun 1992). Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer. 65:891-894.
• Jameel A; Skilton RA; Campbell TA; Chander SK; Coombes RC; Luqmani YA. (1 Feb 1992). Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer. 50:409-415.
• Luqmani YA; Smith J; Coombes RC. (1 Feb 1992). Polymerase chain reaction-aided analysis of gene expression in frozen tissue sections. Anal Biochem. 200:291-295.
• Luqmani YA; Ryall G; Shousha S; Coombes RC. (21 Jan 1992). An immunohistochemical survey of pS2 expression in human epithelial cancers. Int J Cancer. 50:302-304.
• Evans TR; Stein RC; Ford HT; Gazet JC; Chamberlain GV; Coombes RC. (15 Jan 1992). Lactic acidosis. A presentation of metastatic breast cancer arising in pregnancy. Cancer. 69:453-456.
• ABE O; ABE R; ASAISHI K; ENOMOTO K; HATTORI T; INO Y; KIKUCHI K; KOYAMA H; et alSAWA K; UCHINO J; YOSHIDA M; HAYBITTLE JL; VANDEVELDE T; VERMORKEN JB; HARVEY VJ; HOLDAWAY TM; KAY RG; MASON BH; FORBES JF; BASTERT G; SAUERBREI W; SCHEURLEN H; SCHUMACHER M; FOCAN C; LOBELLE JP; PEEK U; OATES GD; POWELL J; DURAND M; MAURIAC L; GELMAN RS; HENDERSON IC; SHAPIRO CL; HANCOCK AK; JACKSON S; RAGAZ J; HENDERSON IC; KORZUN A; WOOD WC; YOSHIMOTO M; BAUM M; HOUGHTON J; HORGAN K; HUGHES L; STEWART HJ; GORDON NH; DAVIS HL; DELOZIER T; MACELESECH J; RAMBERT P; ANDRYSEK O; BARKMANOVA J; OWEN JR; HOWELL A; RIBEIRO GC; SWINDELL R; DEOLIVEIRA CF; CARSTENSEN B; PALSHOF T; JOHANSEN H; KORZENIOWSKI S; SKOLYSZEWSKI J; ANDERSEN KW; DOMBERNOWSKY P; MOURIDSEN HT; ROSE C; CORCORAN N; TRAMPISCH HJ; ABELOFF MD; CARBONE PC; GLICK J; GRAY R; TORMEY DC; BUYSE M; MIGNOLET F; PARIDAENS R; VANDRIEL OJR; SYLVESTER RJ; VANDEVELDE CJH; VANDONGEN JA; WELVAART K; SCANLON EF; SCHURMAN S; CATALANO R; CREECH RH; DESCHRYVER A; MCGREGOR K; YOSEF HMA; MCARDLE CS; SMITH DC; LARA PC; DENT DM; GUDGEON CA; HACKING A; BOCCARDO F; IZUO M; BENTLEY A; DORAN Z; FENTIMAN IS; HAYWARD JL; RUBENS RD; KAUFMANN M; JONAT W; SCHEURLEN H; VONFOURNIER D; KAUFMANN M; KLEFSTROM P; CUZICK J; MARGREITER R; ASSELAIN B; POUILLARD P; BAHI J; MILLA A; SANCHIZ F; CASTIGLIONE M; CAVALLI F; COLLINS J; GELBER RD; GOLDHIRSCH A; ISLEY MR; LINDTNER J; PRICE KN; RUDENSTAM CM; SENN HJ; BLISS JM; CHILVERS CED; COOMBES RC; MARTY M; BOROVIK R; BRUFMAN G; ROBINSON E; PANNUTI F; TAKASHIMA S; YASUTOMI T; HOLM LE; SONOO H; YAMASHITA J; BONTE J; BUZDAR AU; SMITH T; MARTIN P; ROMAIN S; AHMANN D; SCHAID DJ; HAKES T; NORTON L; WITTES R; FOROGLOU P; LISSAIOS B; BONADONNA G; DELVECCHIO M; VALAGUSSA P; VERONESI U; DUBOIS JB; BRUFMAN G; HAYAT H; BIANCO AR; LIPPMAN ME; PIERCE LJ; SIMON R; STEINBERG SM; NOMURA Y; DELAHUERTA R; SAINZ MG; BROWN A; FISHER B; REDMOND C; WOLMARK N; BAUM M; JACKSON IM; PALMER MK; INGLE JN; SCHAID DJ; BENGTSSON NO; LARSSON LG; LYTHGOE JP; SWINDELL R; KISSIN M; BLAMEY RW; MITCHELL AK; ROBERTSON JFR; CASTIGLIONE M; FLUCKIGER H; SENN HJ; NAKAMURA Y; MATHE G; MISSET JL; DESHPANDE N; DIMARTINO L; CLARKE EA; MCLAUGHLIN JR; CLARK RM; LEVINE M; MORIMOTO K; GUNDERSEN S; HAUERJENSEN M; HOST H; CROSSLEY E; DURRANT K; HARRIS A; CLARKE M; COLLINS R; GODWIN J; GRAY R; GREAVES E; HARWOOD C; MEAD G; PETO R; WHEATLEY K; HILL C; LACOUR J; LAPLANCHE A; LE M; SARRAZIN D; SEMIGLAZOV V; BROCKSCHMIDT J; COOPER MR; MEAKIN JW; PANZARELLA T; PRITCHARD KI; TREURNIETDONKER AD; VANPUTTEN WLJ; EASTON D; POWLES TJ; GAZET JC; DOUGLAS P; HACKING A; HOST H; LINDTNER A; NOTTER G; BRYANT AJS; EWING GH; KRUSHEN JL; NISSENMEYER R; FORREST APM; MCDONALD C; STEWART HJ; MOLLER TR; RYDEN S; CARSTENSEN J; HATSCHEK T; SODERBERG M; CARPENTER JT; CRAWLEY J; GREEN S; OSBORNE CK; RUTQVIST LE; WALLGREN A; BRENNER H; HERCBERGS A; DEBOER G; PATERSON AHG; PRITCHARD KI; NAJA A; REID M; SPITTLE M; SENANAYAKE F; MEIER P; TENGRUP I; TENNVALLNITTBY L; CAFFIER H; BEZWODA WR; HOLMBERG L; SEVELDA P; ZIELINSKY CC; JAKESZ R; BUCHANAN RB; CROSS M; DUNN JA; GILLESPIE; KELLY K; MORRISON JM; LITTON A; CHLEBOWSKI RT. (11 Jan 1992). SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY - 133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN .2. LANCET. 339:71-85.
• Coombes RC; Hughes SW; Dowsett M. (1992). 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur J Cancer. 28A:1941-1945.
• Bower M; Stein R; Evans TR; Hedley A; Pert P; Coombes RC. (1992). A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. Eur J Cancer. 28A:888-889.
• Stein RC; Joseph AE; Matlin SA; Cunningham DC; Ford HT; Coombes RC. (1992). A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol. 30:480-482.
• Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC. (1992). An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer. 28:415-420.
• LUQMANI YA; SKILTON R; CAMPBELL T; JAMEEL A; COOMBES RC. (1992). DIFFERENTIAL HYBRIDIZATION AND IMMUNOSCREENING OF EXPRESSION LIBRARIES IN AN ATTEMPT TO IDENTIFY BREAST-CANCER ASSOCIATED MOLECULE. FIBRINOLYSIS. 6:161-169.
• Campbell T; Skilton RA; Coombes RC; Shousha S; Graham MD; Luqmani YA. (Jan 1992). Isolation of a lactoferrin cDNA clone and its expression in human breast cancer. Br J Cancer. 65:19-26.
• Stein RC; Bower M; Law M; Bliss JM; Barton C; Gazet JC; Ford HT; Coombes RC. (1992). Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. Eur J Cancer. 28A:1963-1965.
• Evans TR; Chander SK; Rowlands MG; Coombes RC. (Jan 1992). Oestrone sulphatase activity in mammary tumours and the liver of N-nitrosomethylurea treated rats. Br J Cancer. 65:72-76.
• Ricketts D; Hadcocks L; Fitzek M; Rawson NS; Colston K; Powles TJ; Gazet JC; Coombes RC. (1992). Serum markers for primary and recurrent breast cancer: BCM-EIA, CAM 26 and CAM 29. Tumour Biol. 13:207-216.
• Luqmani YA; Campbell TA; Bennett C; Coombes RC; Paterson IM. (11 Nov 1991). Expression of lactoferrin in human stomach. Int J Cancer. 49:684-687.
• Dowsett M; MacNeill F; Mehta A; Newton C; Haynes B; Jones A; Jarman M; Lonning P; et alPowles TJ; Coombes RC. (Nov 1991). Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 64:887-894.
• Chander SK; McCague R; Luqmani Y; Newton C; Dowsett M; Jarman M; Coombes RC. (1 Nov 1991). Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 51:5851-5858.
• Evans TR; Rowlands MG; Jarman M; Coombes RC. (Oct 1991). Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J Steroid Biochem Mol Biol. 39:493-499.
• Gomm JJ; Smith J; Ryall GK; Baillie R; Turnbull L; Coombes RC. (1 Sep 1991). Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res. 51:4685-4692.
• Coombes RC; Wilkinson JR; Bliss JM; Shah P; Easton DF; Dowsett M. (Aug 1991). 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis. Br J Cancer. 64:247-250.
• Topham C; Glees J; Rawson NS; Woods EM; Coombes RC. (Jul 1991). Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer. 64:179-181.
• Baluch S; Midwood CJ; Griffiths JR; Stubbs M; Coombes RC. (Jun 1991). Monitoring therapeutic response to tamoxifen in NMU-induced rat mammary tumours by 31P MRS. Br J Cancer. 63:901-904.
• MANSI JL; COOMBES RC. (May 1991). TREATMENT OF METASTATIC DISEASE. DIAGN ONCOL. 1:161-167.
• COOMBES RC; FORD HT; GAZET JC. (13 Apr 1991). DIAGNOSING BREAST-CARCINOMA IN YOUNG-WOMEN - REPLY. BRIT MED J. 302:911-911.
• Ricketts D; Turnbull L; Ryall G; Bakhshi R; Rawson NS; Gazet JC; Nolan C; Coombes RC. (1 Apr 1991). Estrogen and progesterone receptors in the normal female breast. Cancer Res. 51:1817-1822.
• BOWER M; COLSTON KW; STEIN RC; HEDLEY A; GAZET JC; FORD HT; COOMBES RC. (23 Mar 1991). TOPICAL CALCIPOTRIOL TREATMENT IN ADVANCED BREAST-CANCER. LANCET. 337:701-702.
• Yelland A; Graham MD; Trott PA; Ford HT; Coombes RC; Gazet JC; Polson NG. (16 Mar 1991). Diagnosing breast carcinoma in young women. BMJ. 302:618-620.
• Gazet JC; Ford HT; Coombes RC. (Feb 1991). Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br J Cancer. 63:279-282.
• STEIN RC; MALKOVSKA V; MORGAN S; GALAZKA A; ANISZEWSKI C; ROY SE; SHEARER RJ; MARSDEN RA; et alBEVAN D; GORDONSMITH EC; COOMBES RC. (Feb 1991). THE CLINICAL EFFECTS OF PROLONGED TREATMENT OF PATIENTS WITH ADVANCED CANCER WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2. BRIT J CANCER. 63:275-278.
• Jones AL; Powles TJ; Forgeson GV; Coombes RC. (1991). A clinical study of nafazatrom in advanced human breast cancer. Cancer Chemother Pharmacol. 27:326-328.
• Mansi JL; Easton D; Berger U; Gazet JC; Ford HT; Dearnaley D; Coombes RC. (1991). Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer. 27:1552-1555.
• Evans C; Stein RC; Davenport J; Dougherty L; Carruthers L; Coombes RC. (1991). Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone. Eur J Cancer. 27:302-303.
• Powles TJ; Trott PA; Cherryman G; Clarke S; Ashley S; Coombes RC; Jones AL; Sinnett HD; et alNash AG. (1991). Fine needle aspiration cytodiagnosis as a pre-requisite for primary medical treatment of breast cancer. Cytopathology. 2:7-12.
• Berger U; McClelland RA; Wilson P; Greene GL; Haussler MR; Pike JW; Colston K; Easton D; et alCoombes RC. (1 Jan 1991). Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 51:239-244.
• Haynes BP; Jarman M; Dowsett M; Mehta A; Lønning PE; Griggs LJ; Jones A; Powles T; et alStein R; Coombes RC. (1991). Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol. 27:367-372.
• Bower M; Stein RC; Hedley A; Davenport J; Colston K; Coombes RC. (1991). The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy. Cancer Chemother Pharmacol. 28:311-312.
• Jones AL; Dowsett MJ; Powles TJ; Gallagher CJ; Coombes RC. (1991). Treatment of advanced breast cancer with miconazole: a potential inhibitor of peripheral oestrogen synthesis. Eur J Cancer. 27:301.
• JONES AL; DOWSETT MJ; POWLES TJ; GALLAGHER CJ; COOMBES RC. (1991). TREATMENT OF ADVANCED BREAST-CANCER WITH MICONAZOLE - A POTENTIAL INHIBITOR OF PERIPHERAL ESTROGEN SYNTHESIS. EUR J CANCER. 27:301-301.
• Coombes RC; Barrett-Lee P; Luqmani Y. (20 Dec 1990). Growth factor expression in breast tissue. J Steroid Biochem Mol Biol. 37:833-836.
• Taylor AH; Ang VT; Jenkins JS; Silverlight JJ; Coombes RC; Luqmani YA. (15 Dec 1990). Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 50:7882-7886.
• Rayter Z; Gazet JC; Ford HT; Easton DF; Coombes RC. (Dec 1990). Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer. Eur J Surg Oncol. 16:486-492.
• Brodie AM; Banks PK; Inkster SE; Dowsett M; Coombes RC. (20 Nov 1990). Aromatase inhibitors and hormone-dependent cancers. J Steroid Biochem Mol Biol. 37:327-333.
• Coombes RC. (Nov 1990). Aromatase inhibitors: where now?. Ann Oncol. 1:399-400.
• Ford MF; Jones M; Scannell T; Powell A; Coombes RC; Evans C. (Oct 1990). Is group psychotherapy feasible for oncology outpatients attenders selected on the basis of psychological morbidity?. Br J Cancer. 62:624-626.
• Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC. (Oct 1990). The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer. 62:679-683.
• JONES AL; POWLES TJ; COOMBES RC; SMITH IE; EASTON D. (Sep 1990). A RANDOMIZED TRIAL OF ADJUVANT AMINOGLUTETHIMIDE VERSUS PLACEBO IN POSTMENOPAUSAL PATIENTS WITH NODE POSITIVE BREAST-CANCER. BRIT J CANCER. 62:521-522.
• STEIN RC; EVANS C; DAVENPORT J; CARRUTHERS L; COOMBES RC. (Sep 1990). COMPARISON OF THE ANTIEMETIC ONDANSETRON WITH DEXAMETHASONE PLUS DOMPERIDONE IN THE PROPHYLAXIS OF CHEMOTHERAPY INDUCED EMESIS REFRACTORY TO DEXAMETHASONE. BRIT J CANCER. 62:523-524.
• JAMEEL A; LUQMANI YA; SKILTON RA; CAMPBELL T; COOMBES RC. (Sep 1990). ISOLATION OF A CDNA SEQUENCE HOMOLOGOUS TO HSP 86 AND ITS EXPRESSION IN HUMAN BREAST. BRIT J CANCER. 62:546-547.
• STEIN RC; MALKOWSKA V; MORGAN S; ANISZEWSKI C; GALAZKA A; BEVAN D; GORDONSMITH EC; COOMBES RC. (Sep 1990). THE EFFECTS OF PROLONGED TREATMENT OF PATIENTS WITH ADVANCED CANCER WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 (IL2). BRIT J CANCER. 62:501-501.
• CHANDER SK; MCCAGUE R; COOMBES RC. (Sep 1990). THE INVITRO AND INVIVO TESTING OF PYRROLIDINO-IODO-TAMOXIFEN, A NEW ANALOG OF THE ANTIESTROGEN TAMOXIFEN. BRIT J CANCER. 62:493-493.
• Coombes RC; Schein PS; Chilvers CE; Wils J; Beretta G; Bliss JM; Rutten A; Amadori D; et alCortes-Funes H; Villar-Grimalt A. (Aug 1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol. 8:1362-1369.
• COOMBES RC; SCHEIN PS; CHILVERS CED; WILS J; BERETTA G; BLISS JM; RUTTEN A; AMADORI D; et alCORTESFUNES H; VILLARGRIMALT A; MCARDLE C; RAUSCHECKER HF; BOVEN E; VASSILOPOULOS P; WELVAART K; FERREIRA EP; WIIG J; GISSELBRECHT C; ROUGIER P; WOODS EMA. (Aug 1990). A RANDOMIZED TRIAL COMPARING ADJUVANT FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN WITH NO TREATMENT IN OPERABLE GASTRIC-CANCER. J CLIN ONCOL. 8:1362-1369.
• Shearer RJ; Davies JH; Dowsett M; Malone PR; Hedley A; Cunningham D; Coombes RC. (Aug 1990). Aromatase inhibition in advanced prostatic cancer: preliminary communication. Br J Cancer. 62:275-276.
• Dowsett M; Stein RC; Mehta A; Coombes RC. (May 1990). Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf). 32:623-634.
• Berger U; Khaghani A; Pomerance A; Yacoub MH; Coombes RC. (May 1990). Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol. 93:609-614.
• Barrett-Lee P; Travers M; Luqmani Y; Coombes RC. (Apr 1990). Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer. 61:612-617.
• Stein RC; Dowsett M; Cunningham DC; Davenport J; Ford HT; Gazet JC; von Angerer E; Coombes RC. (Mar 1990). Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer. 61:451-453.
• Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC. (1 Mar 1990). Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 50:1381-1384.
• Stubbs M; Coombes RC; Griffiths JR; Maxwell RJ; Rodrigues LM; Gusterson BA. (Feb 1990). 31P-NMR spectroscopy and histological studies of the response of rat mammary tumours to endocrine therapy. Br J Cancer. 61:258-262.
• COOMBES RC; MURRAY P; LUQMANI Y. (Feb 1990). THE PROGNOSTIC-SIGNIFICANCE OF TRANSCRIPTS FOR TRANSFORMING GROWTH FACTOR-ALPHA AND FACTOR-BETA AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN PRIMARY BREAST-CANCER. EUR J CANCER. 26:159-159.
• Skilton RA; Earl HM; Gore ME; McIlhinney RA; Gusterson BA; Wilson P; Coombes RC; Neville AM. (1990). Characterization of monoclonal antibodies reactive with normal resting, lactating and neoplastic human breast. Tumour Biol. 11:20-38.
• Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL. (1990). Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer. 26:824-827.
• Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC. (1990). Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol. 26:75-78.
• Ricketts D; Coombes RC. (Dec 1989). What's new in steroid receptor immunocytochemistry in clinical oncology?. Pathol Res Pract. 185:935-941.
• Earl HM; McIlhinney RA; Wilson P; Gusterson BA; Coombes RC. (1 Nov 1989). Immunohistochemical study of beta- and kappa-casein in the human breast and breast carcinomas, using monoclonal antibodies. Cancer Res. 49:6070-6076.
• Berger U; Wilson P; Thethi S; McClelland RA; Greene GL; Coombes RC. (15 Sep 1989). Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res. 49:5176-5179.
• DAVIES JH; DOWSETT M; COOMBES RC; SHEARER RJ. (Sep 1989). AROMATASE INHIBITION BY 4-HYDROXYANDROSTENEDIONE IN ADVANCED PROSTATIC-CANCER. BRIT J CANCER. 60:492-492.
• CUNNINGHAM D; SAUVEN P; PARKER M; GLAZER G; COLEMAN D; COULTER C; CUNNINGHAM D; LENNOX M; et alHERMONTAYLOR J; COOMBES RC; KIRKHAM JS; ROSIN RD. (Sep 1989). INTRAPERITONEAL CISPLATIN - A NEW APPROACH TO THE ADJUVANT TREATMENT OF GASTRIC-CANCER. BRIT J CANCER. 60:458-458.
• HAYNES BP; GRIGGS LJ; JARMAN M; COOMBES RC; LONNING PE; POWLES TJ. (Sep 1989). PHARMACOKINETICS OF PYRIDOGLUTETHIMIDE, A NEW AROMATASE INHIBITOR. BRIT J CANCER. 60:465-465.
• Skilton RA; Luqmani YA; McClelland RA; Coombes RC. (Aug 1989). Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer. 60:168-175.
• Silva MC; Rowlands MG; Dowsett M; Gusterson B; McKinna JA; Fryatt I; Coombes RC. (15 May 1989). Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res. 49:2588-2591.
• STEIN RC; DOWSETT M; HEDLEY A; COOMBES RC. (May 1989). 4-HYDROXYANDROSTENEDIONE ALONE AND IN COMBINATION WITH ZOLADEX IN PREMENOPAUSAL BREAST-CANCER. BRIT J CANCER. 59:824-824.
• LUQMANI YA; SKILTON R; MCCLELLAND R; COOMBES RC. (May 1989). EVALUATION OF AN MESSENGER-RNA SELECTIVELY EXPRESSED IN HUMAN-BREAST CANCER. BRIT J CANCER. 59:820-821.
• COOMBES RC. (May 1989). GROWTH-CONTROL OF THE NORMAL BREAST. BRIT J CANCER. 59:815-815.
• STEIN RC; DOWSETT M; DAVENPORT J; HEDLEY A; COOMBES RC. (May 1989). PRELIMINARY-STUDY OF AROMATASE INHIBITOR CGS16949A IN ADVANCED POST-MENOPAUSAL BREAST-CANCER. BRIT J CANCER. 59:823-824.
• Mansi JL; Berger U; McDonnell T; Pople A; Rayter Z; Gazet JC; Coombes RC. (Apr 1989). The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol. 7:445-449.
• COOMBES RC; COLSTON KW. (11 Mar 1989). VITAMIN-D AND BREAST-CANCER - REPLY. LANCET. 1:550-550.
• Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC. (1 Mar 1989). Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49:1306-1312.
• Shah P; van der Meide PH; Borman T; Schroeder N; Bliss JM; Coombes RC. (Feb 1989). Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. Br J Cancer. 59:206-209.
• Colston KW; Berger U; Coombes RC. (28 Jan 1989). Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1:188-191.
• COLSTON KW; BERGER U; COOMBES RC. (28 Jan 1989). POSSIBLE ROLE FOR VITAMIN-D IN CONTROLLING BREAST-CANCER CELL-PROLIFERATION. LANCET. 1:188-192.
• COOMBES RC; STEIN RC; DOWSETT M. (1989). AROMATASE INHIBITORS IN HUMAN-BREAST CANCER. P ROY SOC EDINB B. 95:283-291.
• Hickish T; Cunningham D; Haydock A; Coombes RC. (1989). Experience with intermediate-dose (110-120 mg/m2) epirubicin. Cancer Chemother Pharmacol. 24:61-64.
• Colston KW; Berger U; Wilson P; Hadcocks L; Naeem I; Earl HM; Coombes RC. (Nov 1988). Mammary gland 1,25-dihydroxyvitamin D3 receptor content during pregnancy and lactation. Mol Cell Endocrinol. 60:15-22.
• Berger U; Wilson P; McClelland RA; Colston K; Haussler MR; Pike JW; Coombes RC. (Sep 1988). Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 67:607-613.
• Mansi JL; Mesker WE; McDonnell T; Van Driel-Kulker AM; Ploem JS; Coombes RC. (9 Aug 1988). Automated screening for micrometastases in bone marrow smears. J Immunol Methods. 112:105-111.
• Mansi JL; Earl HM; Powles TJ; Coombes RC. (Jul 1988). Tests for detecting recurrent disease in the follow-up of patients with breast cancer. Breast Cancer Res Treat. 11:249-254.
• Berger U; Bettelheim R; Mansi JL; Easton D; Coombes RC; Neville AM. (Jul 1988). The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol. 90:1-6.
• Travers MT; Barrett-Lee PJ; Berger U; Luqmani YA; Gazet JC; Powles TJ; Coombes RC. (11 Jun 1988). Growth factor expression in normal, benign, and malignant breast tissue. Br Med J (Clin Res Ed). 296:1621-1624.
• Gazet JC; Markopoulos C; Ford HT; Coombes RC; Bland JM; Dixon RC. (28 May 1988). Tamoxifen and breast cancer in the elderly. Lancet. 1:1218.
• GAZET JC; MARKOPOULOS C; FORD HT; COOMBES RC; BLAND JM; DIXON RC. (28 May 1988). TAMOXIFEN AND BREAST-CANCER IN THE ELDERLY. LANCET. 1:1218-1218.
• Markopoulos C; Berger U; Wilson P; Gazet JC; Coombes RC. (14 May 1988). Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed). 296:1349-1351.
• Gazet JC; Markopoulos C; Ford HT; Coombes RC; Bland JM; Dixon RC. (26 Mar 1988). Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1:679-681.
• Mansi JL; Berger U; Wilson P; Shearer R; Coombes RC. (Mar 1988). Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urol. 139:545-548.
• MARKOPOULOS C; BERGER U; GAZET JC; WILSON P; COOMBES RC. (Feb 1988). CYCLICAL EXPRESSION OF ESTROGEN-RECEPTOR IN NORMAL BREAST EPITHELIAL-CELLS DOES NOT OCCUR IN BREAST-CANCER. BRIT J CANCER. 57:226-227.
• MANSI J; BERGER U; WILSON P; SHEARER R; COOMBES RC. (Feb 1988). DETECTION OF TUMOR-CELLS IN BONE-MARROW OF PATIENTS WITH PROSTATIC-CARCINOMA BY IMMUNOCYTOCHEMICAL METHODS. BRIT J CANCER. 57:227-227.
• TRAVERS MT; BARRETTLEE PJ; LUQMANI Y; COOMBES RC. (Feb 1988). PLATELET DERIVED GROWTH-FACTOR AND INSULIN-LIKE GROWTH FACTOR-II EXPRESSION IN HUMAN-BREAST BIOPSIES. BRIT J CANCER. 57:228-228.
• ESILVA MC; ROWLANDS MG; DOWSETT M; BERGER U; SIMPSON ER; MENDELSON CR; FRAYTT I; COOMBES RC. (Feb 1988). THE SIGNIFICANCE OF INTRATUMORAL AROMATASE [A] (ESTROGEN [E2] SYNTHETASE) IN HUMAN-BREAST CANCER [BC]. BRIT J CANCER. 57:227-227.
• BARRETTLEE PJ; TRAVERS MT; LUQMANI YA; COOMBES RC. (Feb 1988). TRANSFORMING GROWTH FACTOR-ALPHA AND FACTOR-BETA (TGFS) IN BIOPSIES OF NORMAL AND MALIGNANT HUMAN-BREAST. BRIT J CANCER. 57:223-223.
• Rodrigues LM; Midwood CJ; Coombes RC; Stevens AN; Stubbs M; Griffiths JR. (1 Jan 1988). 31P-nuclear magnetic resonance spectroscopy studies of the response of rat mammary tumors to endocrine therapy. Cancer Res. 48:89-93.
• Brodie AM; Dowsett M; Coombes RC. (1988). Aromatase inhibitors as new endocrine therapy for breast cancer. Cancer Treat Res. 39:51-65.
• Vincent MD; Powles TJ; Coombes RC; McElwain TJ. (1988). Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol. 21:255-260.
• Barrett-Lee PJ; Travers MT; McClelland RA; Luqmani Y; Coombes RC. (15 Dec 1987). Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res. 47:6653-6659.
• Berger U; Wilson P; McClelland RA; Colston K; Haussler MR; Pike JW; Coombes RC. (15 Dec 1987). Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res. 47:6793-6799.
• COOMBES RC; GOSS PE; DOWSETT M; HUTCHINSON G; CUNNINGHAM D; JARMAN M; BRODIE AMH. (Dec 1987). 4-HYDROXYANDROSTENEDIONE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER. TUMORDIAGN THER. 8:271-273.
• Berger U; Wilson P; McClelland RA; Davidson J; Coombes RC. (Dec 1987). Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol. 18:1263-1267.
• McClelland RA; Berger U; Wilson P; Powles TJ; Trott PA; Easton D; Gazet JC; Coombes RC. (15 Nov 1987). Presurgical determination of estrogen receptor status using immunocytochemically stained fine needle aspirate smears in patients with breast cancer. Cancer Res. 47:6118-6122.
• Berger U; Mansi JL; Wilson P; Coombes RC. (Nov 1987). Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. J Clin Oncol. 5:1779-1782.
• Cunningham D; Gazet JC; Ford HT; Coombes RC. (Nov 1987). Oral gestrinone: a novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer. Cancer Treat Rep. 71:1091-1092.
• Mansi JL; Berger U; Easton D; McDonnell T; Redding WH; Gazet JC; McKinna A; Powles TJ; et alCoombes RC. (31 Oct 1987). Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J (Clin Res Ed). 295:1093-1096.
• Coombes RC; Rothwell NJ; Shah P; Stock MJ. (Oct 1987). Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat. Biosci Rep. 7:791-799.
• Coombes RC; Powles TJ; Berger U; Wilson P; McClelland RA; Gazet JC; Trott PA; Ford HT. (26 Sep 1987). Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet. 2:701-703.
• WARD MC; WARD CS; GAZET JC; FORD HT; ASHLEY S; MACDONALD JS; POWLES TJ; COOMBES RC. (Sep 1987). FALSE NEGATIVE MAMMOGRAPHY IN PATIENTS WITH BREAST-CANCER. CLIN RADIOL. 38:556-556.
• GRIFFITHS JR; BHUJWALLA Z; COOMBES RC; MAXWELL RJ; MIDWOOD CJ; RODRIGUES LM; STUBBS M; TOZER GM. (Sep 1987). NMR-SPECTROSCOPY OF CANCER. HUM TOXICOL. 6:419-419.
• CUNNINGHAM D; EVANS C; POPLE A; DEARLING J; CHAPPELL D; COOMBES RC. (Aug 1987). COMPARISON OF THE ANTIEMETIC EFFICACY OF DOMPERIDONE, METOCLOPRAMIDE AND DEXAMETHASONE IN OUT-PATIENTS RECEIVING CHEMOTHERAPY. BRIT J CANCER. 56:226-226.
• BARRETTLEE PJ; TRAVERS MT; MCDONNELL TA; COOMBES RC. (Aug 1987). EXPRESSION OF ESTROGEN-RECEPTOR MESSENGER-RNA IN HUMAN-BREAST CANCER BIOPSIES. BRIT J CANCER. 56:211-212.
• CUNNINGHAM D; HAWTHORN J; POPLE A; GAZET JC; FORD HT; CHALLONER T; COOMBES RC. (Aug 1987). GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST, IS ANTIEMETIC IN PATIENTS RECEIVING CYTOTOXIC DRUGS. BRIT J CANCER. 56:217-217.
• SHAH P; COOMBES RC. (Aug 1987). THE EFFECT OF HUMAN RECOMBINANT TUMOR-NECROSIS-FACTOR (RHUTNF) AND RAT GAMMA INTERFERON (RIFN-GAMMA) ON NITROSOMETHYLUREA (NMU) INDUCED RAT MAMMARY-TUMOR GROWTH. BRIT J CANCER. 56:190-191.
• Coombes RC; Goss PE; Dowsett M; Hutchinson G; Cunningham D; Jarman M; Brodie AM. (Jul 1987). 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids. 50:245-252.
• Bellamy EA; Nicholas D; Ward M; Coombes RC; Powles TJ; Husband JE. (Jul 1987). Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast. Clin Radiol. 38:351-355.
• Cunningham D; Hawthorn J; Pople A; Gazet JC; Ford HT; Challoner T; Coombes RC. (27 Jun 1987). Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1:1461-1463.
• Coombes RC; Powles TJ; Easton D; Chilvers C; Ford HT; Smith IE; McKinna A; White H; et alBradbeer J; Yarnold J. (1 May 1987). Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res. 47:2494-2497.
• COOMBES RC; POWLES TJ; EASTON D; CHILVERS C; FORD HT; SMITH IE; MCKINNA A; WHITE H; et alBRADBEER J; YARNOLD J; NASH A; BETTELHEIM R; DOWSETT M; GAZET JC. (1 May 1987). ADJUVANT AMINOGLUTETHIMIDE THERAPY FOR POSTMENOPAUSAL PATIENTS WITH PRIMARY BREAST-CANCER. CANCER RES. 47:2496-2497.
• Rowlands MG; Foster AB; Mann J; Pietrzak B; Wilkinson J; Coombes RC. (Apr 1987). Synthesis and evaluation of analogues of 4-androstene-3,17-dione as aromatase inhibitors. Steroids. 49:371-382.
• Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC. (1 Apr 1987). Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 47:1957-1961.
• BRODIE AMH; DOWSETT M; COOMBES RC. (Mar 1987). AROMATASE INHIBITORS AND CONTROL OF BREAST-CANCER. P AM ASSOC CANC RES. 28:472-473.
• CUNNINGHAM D; POWLES TJ; DOWSETT M; FORD HT; GAZET JC; HUTCHISON G; BRODIE AM; COOMBES RC. (Mar 1987). ORAL CGP 32349 (4-HYDROXYANDROSTENEDIONE) HAS ANTITUMOR-ACTIVITY IN BREAST-CANCER. BRIT J CANCER. 55:340-340.
• MANSI JL; BERGER U; MCDONNELL T; COOMBES RC. (Mar 1987). REPEAT BONE-MARROW ASPIRATES IN PATIENTS WITH PRIMARY BREAST-CANCER. BRIT J CANCER. 55:340-341.
• Brodie AM; Coombes RC; Dowsett M. (1987). Aromatase inhibitors: basic and clinical studies. J Steroid Biochem. 27:899-903.
• Neville AM; Coombes RC. (1987). Biochemical and immunologic diagnosis of cancer. Breast cancer. Tumour Biol. 8:116-119.
• NEVILLE AM; COOMBES RC. (1987). BREAST-CANCER. TUMOR BIOL. 8:116-119.
• COOMBES RC; MCCLELLAND RA; BERGER U; WILSON P. (1987). ESTROGEN-RECEPTOR IMMUNOCYTOCHEMICAL ASSAY (ERICA) IN FINE NEEDLE ASPIRATES FROM BREAST-CANCER TISSUE AND BONE-MARROW ASPIRATES. TUMOR BIOL. 8:284-284.
• BERGER U; WILSON P; COLSTON K; COOMBES RC; PIKE JW; HAUSSLER MR. (1987). IMMUNOCYTOCHEMICAL DETECTION OF 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR IN NORMAL HUMAN-TISSUES. BONE. 8:264-264.
• Griffiths JR; Bhujwalla Z; Coombes RC; Maxwell RJ; Midwood CJ; Morgan RJ; Nias AH; Perry P; et alPrior M; Prysor-Jones RA. (1987). Monitoring cancer therapy by NMR spectroscopy. Ann N Y Acad Sci. 508:183-199.
• Cunningham D; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Ford HT; Gazet JC; Coombes RC. (1987). Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol. 20:253-255.
• Jarman M; Leung OT; Leclercq G; Devleeschouwer N; Stoessel S; Coombes RC; Skilton RA. (Nov 1986). Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts. Anticancer Drug Des. 1:259-268.
• Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC. (Nov 1986). Aromatase inhibitors and their potential clinical significance. J Steroid Biochem. 25:859-865.
• Ward MC; Roberts KR; Westwood JH; Coombes RC; McCready VR. (Nov 1986). The effect of chelating agents on the distribution of monoclonal antibodies in mice. J Nucl Med. 27:1746-1750.
• Vincent MD; Powles TJ; Skeet R; Ashley S; Coombes RC; Gibb J; Clarke S; Thomas HL; et alAdcock H. (Sep 1986). An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol. 22:1059-1065.
• Wilkinson JR; Williams JC; Singh D; Goss PE; Easton D; Coombes RC. (Sep 1986). Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res. 46:4862-4865.
• Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC. (Sep 1986). Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 46:4823-4826.
• YIU CY; BAKER LA; ROBERTS K; WESTWOOD JH; COOMBES RC; CLARK CG. (Sep 1986). XENOGRAFT LOCALIZATION OF A MONOCLONAL-ANTIBODY REACTING WITH COLORECTAL-CANCER. BRIT J CANCER. 54:553-553.
• McClelland RA; Berger U; Miller LS; Powles TJ; Coombes RC. (Aug 1986). Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol. 4:1171-1176.
• McClelland RA; Berger U; Miller LS; Powles TJ; Jensen EV; Coombes RC. (Aug 1986). Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res. 46:4241s-4243s.
• MCCLELLAND RA; BERGER U; MILLER LS; POWLES TJ; JENSEN EV; COOMBES RC. (Aug 1986). IMMUNOCYTOCHEMICAL ASSAY FOR ESTROGEN-RECEPTOR - RELATIONSHIP TO OUTCOME OF THERAPY IN PATIENTS WITH ADVANCED BREAST-CANCER. CANCER RES. 46:4241-4243.
• Coombes RC; Buckman R; Forrester JA; Shepherd V; O'Hare MJ; Vincent M; Powles TJ; Neville AM. (Aug 1986). In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res. 46:4217-4220.
• BELLAMY EA; NICHOLAS D; WARD M; COOMBES RC; POWLES TJ; HUSBAND JE. (Aug 1986). THE ADVANTAGES OF COMPUTED-TOMOGRAPHY OVER CONVENTIONAL RADIOLOGY IN MONITORING THE TREATMENT RESPONSE OF LYTIC BONY METASTASES. BRIT J RADIOL. 59:805-805.
• Colston K; Wilkinson JR; Coombes RC. (Jul 1986). 1,25-Dihydroxyvitamin D3 binding in estrogen-responsive rat breast tumor. Endocrinology. 119:397-403.
• COOMBES RC; FOWLES TJ; DOWSETT M; BRODIE AMH. (Jul 1986). CLINICAL-STUDIES WITH 4-HYDROXYANDROSTENEDIONE IN BREAST-CANCER PATIENTS. ANTICANCER RES. 6:876-876.
• Yiu CY; Baker L; Gusterson BA; Ward M; Pocock R; Summerhayes I; Coombes RC; Clark CG. (Jul 1986). Monoclonal antibodies reacting with colorectal tumours. Anticancer Res. 6:721-724.
• Goss PE; Ashley S; Powles TJ; Coombes RC. (Jun 1986). High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. Cancer Treat Rep. 70:777-779.
• ROWLANDS MG; JARMAN M; MANN J; PIETRZAK B; COOMBES RC. (Jun 1986). INHIBITION OF HUMAN PLACENTAL AROMATASE AND RAT PROSTATIC 5-ALPHA-REDUCTASE BY 4-FLUOROANDROSTENEDIONE. EUR J CANCER CLIN ON. 22:739-739.
• DOWSETT M; MCGARRICK GE; HARRIS AL; COOMBES RC; SMITH IE; JEFFCOATE SL. (Jun 1986). THE PROGNOSTIC-SIGNIFICANCE OF HYPERPROLACTINEMIA IN BREAST-CANCER. EUR J CANCER CLIN ON. 22:720-720.
• Vold BS; Kraus LE; Rimer VG; Coombes RC. (Jun 1986). Use of a monoclonal antibody to detect elevated levels of a modified nucleoside, N-[9-(beta-D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine, in the urine of breast cancer patients. Cancer Res. 46:3164-3167.
• Goss PE; Jarman M; Wilkinson JR; Coombes RC. (Feb 1986). Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J Steroid Biochem. 24:619-622.
• Powles TJ; Coombes RC; Smith IE; Chilvers C; Easton D; Thomas L; Adcock H; Gazet JC; et alNash AG; Bradbeer J. (1986). A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer. Breast Cancer Res Treat. 7 Suppl:S37-S40.
• POWLES TJ; COOMBES RC; SMITH IE; CHILVERS C; EASTON D; THOMAS L; ADCOCK H; GAZET JC; et alNASH AG; BRADBEER J; MCKINNA JA. (1986). A DOUBLE-BLIND RANDOMIZED CLINICAL-TRIAL OF ADJUVANT AMINOGLUTETHIMIDE VERSUS PLACEBO GIVEN TO POST MENOPAUSAL PATIENTS WITH HISTOLOGICALLY CONFIRMED STAGE-II BREAST-CANCER. BREAST CANCER RES TR. 7:37-40.
• Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC. (Jan 1986). Aromatase inhibitors and the treatment of breast cancer. J Steroid Biochem. 24:91-97.
• Neville AM; Monaghan P; McIlhinney RA; Gusterson B; Coombes RC. (1986). Monoclonal antibodies in the detection and treatment of breast cancer micrometastases. Monogr Pathol. 193-205.
• Coombes RC; Berger U; Mansi J; Redding H; Powles TJ; Neville AM; McKinna A; Nash AG; et alGazet JC; Ford HT. (1986). Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. NCI Monogr. 51-53.
• ROBERTS KR; WARD MC; SOO KC; WESTWOOD JM; CARTER R; GUSTERSON B; OZANNE B; COOMBES RC; et alMCCREADY VR; OTT RJ. (1986). RADIOIMMUNOLYMPHOSCINTIGRAPHY OF PATIENTS WITH HEAD AND NECK-CARCINOMA AND BREAST-CARCINOMA. TUMOR BIOL. 7:321-321.
• Goodall AB; Evans CJ; Trivedi D; Coombes RC; Chantler SM. (Aug 1985). Detection of Ca antigen in sera from normal individuals and patients with benign and malignant breast disease. Br J Cancer. 52:177-182.
• Vincent MD; Clink HM; Coombes RC; Smith IE; Kandler R; Powles TJ. (13 Jul 1985). Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. Br Med J (Clin Res Ed). 291:105-106.
• Gazet JC; Rainsbury RM; Ford HT; Powles TJ; Coombes RC. (15 Jun 1985). Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed). 290:1793-1795.
• Coombes RC; Powles TJ; Muindi J; Hunt J; Ward M; Perez D; Neville AM. (Apr 1985). Trilostane therapy for advanced breast cancer. Cancer Treat Rep. 69:351-354.
• Williams JC; Gusterson BA; Monaghan P; Coombes RC; Rudland PS. (Feb 1985). Isolation and characterization of clonal cell lines from a transplantable metastasizing rat mammary tumor, TR2CL. J Natl Cancer Inst. 74:415-428.
• GROSS P; COOMBES RC; POWLES TJ; DOWSETT M; BRODIE A. (1985). 4-HYDROXYANDROSTENEDIONE - A NEW TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER. BRIT J CANCER. 52:421-421.
• RODRIGUES JL; STEVENS AN; WILKINSON J; COOMBES RC; GRIFFITHS JR. (1985). CHEMICALLY-INDUCED MAMMARY-TUMORS - A P-31 NMR-STUDY OF GROWTH AND THERAPY. BIOCHEM SOC T. 13:887-888.
• MCCLELLAND RA; JENSEN E; MILLER L; BERGER U; COOMBES RC. (1985). COMPARISON OF AN IMMUNOPEROXIDASE AND A BIOCHEMICAL TECHNIQUE IN ASSESSING ESTROGEN-RECEPTOR CONTENT OF HUMAN-BREAST TUMORS. BRIT J CANCER. 52:419-420.
• YIU CY; WARD M; BAKER L; SUMMERHAYES I; COOMBES RC; BOULOUS PB; CLARK CG. (1985). MONOCLONAL-ANTIBODIES REACTING WITH COLORECTAL TUMORS. ANTICANCER RES. 5:608-608.
• WARD M; CLARKE D; ROBERTS K; WESTWOOD JH; COOMBES RC. (1985). RADIOIMMUNOLOCALIZATION OF METASTATIC BREAST-CARCINOMA IN PATIENTS. ANTICANCER RES. 5:608-608.
• WILKINSON JR; COOMBES RC. (1985). SUITABILITY OF NMU RAT MODEL FOR TESTING ENDOCRINE AGENTS FOR BREAST-CANCER. BRIT J CANCER. 52:427-427.
• Perez DJ; Powles TJ; Smith IE; Vincent MD; Ashley S; Gordon C; Gibb J; Clarke S; et alCoombes RC. (1985). The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 15:278-282.
• WARD M; ROBERTS K; WESTWOOD J; MCCREADY VR; COOMBES RC. (1985). THE STABILITY AND TISSUE FIXATION OF AN INDIUM LABELED MOUSE MONOCLONAL-ANTIBODY. ANTICANCER RES. 5:608-608.
• Waxman JH; Harland SJ; Coombes RC; Wrigley PF; Malpas JS; Powles T; Lister TA. (1985). The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol. 15:171-173.
• HARLAND SJ; WAXMAN JH; REES L; FORD HT; GAZET JC; NASH A; POWLES TJ; COOMBES RC. (1985). THE TREATMENT OF PREMENOPAUSAL PATIENTS WITH BREAST-CANCER WITH BUSERELIN NASAL SPRAY. BRIT J CANCER. 52:421-421.
• Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A. (1 Dec 1984). 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 2:1237-1239.
• Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC. (23 Jun 1984). Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet. 1:1369-1373.
• Freake HC; Abeyasekera G; Iwasaki J; Marcocci C; MacIntyre I; McClelland RA; Skilton RA; Easton DF; et alCoombes RC. (Apr 1984). Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res. 44:1677-1681.
• COOMBES RC; GOSS P; BRODIE A. (1984). 4-HYDROXYANDROSTENEDIONE - A POSSIBLE NEW TREATMENT FOR BREAST-CANCER. J STEROID BIOCHEM. 20:1631-1631.
• GOSS P; COOMBES RC; POWLES TJ; DOWSETT M; BRODIE A. (1984). 4-HYDROXYANDROSTENEDIONE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER. BREAST CANCER RES TR. 4:352-352.
• GORE ME; GUSTERSON BA; COOMBES RC; MCILHINNEY RAJ. (1984). A STUDY OF SECRETORY COMPONENT IN BREAST-CANCER USING MONOCLONAL AND POLYCLONAL ANTISERA. BRIT J CANCER. 50:261-262.
• PEREZ DJ; POWLES TJ; MCCREADY VR; MACDONALD JS; COOMBES RC. (1984). CLINICAL EFFICACY OF BONE IMAGING AND X-RAYS IN BREAST-CANCER. BRIT J RADIOL. 57:1051-1051.
• EARL HM; COOMBES RC; SCHEIN PS. (1984). CYTO-TOXIC CHEMOTHERAPY FOR CANCER OF THE STOMACH. CLIN ONCOLO. 3:351-369.
• BUCKMAN R; COOMBES RC; FORESTER AJ; SHEPHERD V; MCILHINNEY RAJ; NEVILLE AM. (1984). ELIMINATION OF MALIGNANT-CELLS FROM BONE-MARROW IN AUTOLOGOUS RESCUE. P AM ASSOC CANC RES. 25:156-156.
• BUCKMAN R; COOMBES RC; FORESTER AJ; SHEPHERD V; MCILHINNEY RAJ; NEVILLE AM. (1984). ELIMINATION OF MALIGNANT-CELLS FROM BONE-MARROW IN AUTOLOGOUS RESCUE (ABMT). BRIT J CANCER. 50:567-567.
• MORRIS AJR; OSULLIVAN JP; MILLARD FJC; HUMBERSTONE AM; HUNT J; POWLES TJ; COOMBES RC. (1984). ENDOBRONCHIAL METASTASIS FROM CARCINOMA OF THE BREAST - A COMMON SITE FOR RECURRENCE. THORAX. 39:218-218.
• MCCLELLAND RA; POWLES TJ; COOMBES RC. (1984). ESTROGEN-RECEPTORS AND PROGNOSIS IN DISSEMINATED BREAST-CANCER. BRIT J CANCER. 50:262-262.
• NEVILLE AM; COOMBES RC. (1984). ETHICS AND RESEARCH - DETECTION OF MICRO-METASTASES - REPLY. LANCET. 1:454-454.
• Buckman R; Redding WH; Dearnaley DP; Smith S; Coombes RC. (Jan 1984). Evaluation of a rosetting method in detection of breast cancer cells. Br J Cancer. 49:103-106.
• SLACK N; RAINSBURY RM; WESTWOOD JH; COOMBES RC; NEVILLE AM; OTT RJ; KALIRAI TS; MCCREADY VR; et alGAZET JC. (1984). FACTORS INFLUENCING THE UPTAKE OF A NEW MONOCLONAL-ANTIBODY (LICR-LON-M8) IN SKELETAL METASTASES FROM BREAST-CARCINOMA. J NUCL MED. 25:P17-P17.
• Perez DJ; Powles TJ; Gazet JC; Ford HT; Coombes RC. (1984). Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. Cancer Chemother Pharmacol. 13:36-38.
• COOMBES RC; RAINSBURY R; REDDING WH; NEVILLE AM. (1984). NEW APPROACHES TO BREAST-CANCER - THE POTENTIAL OF MONOCLONAL-ANTIBODIES. BRIT J CANCER. 49:380-381.
• WAXMAN JH; SLEVIN ML; COOMBES RC; HARLAND S; MALPAS JS; WRIGLEY PMF; LISTER TA. (1984). THE TREATMENT OF ADVANCED BREAST-CANCER WITH AN ANALOG OF GONADOTROPIN-RELEASING HORMONE. BRIT J CANCER. 49:390-390.
• Redding WH; Coombes RC; Monaghan P; Clink HM; Imrie SF; Dearnaley DP; Ormerod MG; Sloane JP; et alGazet JC; Powles TJ. (3 Dec 1983). Detection of micrometastases in patients with primary breast cancer. Lancet. 2:1271-1274.
• Gore ME; Skilton RA; Coombes RC. (Dec 1983). Antibody-dependent-cellular-cytotoxicity against cultured human breast cancer cells mediated by human effector cells using monoclonal and polyclonal antibodies. Br J Cancer. 48:877-879.
• Morris AJ; O'Sullivan JP; Millard FJ; Humberstone AM; Hunt J; Gazet JC; Powles TJ; Ford HT; et alCoombes RC. (Nov 1983). Fibreoptic bronchoscopy as an aid to diagnosis of respiratory symptoms in breast cancer patients. Br J Cancer. 48:731-734.
• Jarman M; Foster AB; Goss PE; Griggs LJ; Howe I; Coombes RC. (Nov 1983). Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite. Biomed Mass Spectrom. 10:620-625. DOI.
• Rainsbury RM; Ott RJ; Westwood JH; Kalirai TS; Coombes RC; McCready VR; Neville AM; Gazet JC. (22 Oct 1983). Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111. Lancet. 2:934-938.
• Perez DJ; Powles TJ; Milan J; Gazet JC; Ford HT; McCready VR; MacDonald JS; Coombes RC. (10 Sep 1983). Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 2:613-616.
• Coombes RC; Dady P; Parsons C; McCready VR; Ford HT; Gazet JC; Powles TJ. (15 Aug 1983). Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 52:610-614.
• Dowsett M; McGarrick GE; Harris AL; Coombes RC; Smith IE; Jeffcoate SL. (Jun 1983). Prognostic significance of serum prolactin levels in advanced breast cancer. Br J Cancer. 47:763-769.
• Dearnaley DP; Ormerod MG; Sloane JP; Lumley H; Imrie S; Jones M; Coombes RC; Neville AM. (May 1983). Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J R Soc Med. 76:359-364.
• Muindi J; Coombes RC; Golding S; Powles TJ; Khan O; Husband J. (Apr 1983). The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol. 56:233-236.
• Ott RJ; Grey LJ; Zivanovic MA; Flower MA; Trott NG; Moshakis V; Coombes RC; Neville AM; et alOrmerod MG; Westwood JH; McCready VR. (Feb 1983). The limitations of the dual radionuclide subtraction technique for the external detection of tumours by radioiodine-labelled antibodies. Br J Radiol. 56:101-108.
• Harris AL; Powles TJ; Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer CL; Morgan M; et alWhite H; Parsons CA; McKinna JA. (Jan 1983). Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol. 19:11-17.
• Coombes RC; Perez D; Gazet JC; Ford HT; Powles TJ. (1983). Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol. 10:194-195.
• RAINSBURY RM; FOSTER C; COOMBES RC; NEVILLE AM; MCCREADY VR. (1983). HUMAN-BREAST CARCINOMA DETECTION USING A RADIOLABELED MONOCLONAL-ANTIBODY. BRIT J RADIOL. 56:508-508.
• RAINSBURY RM; FOSTER C; COOMBES RC; GAZET JC; NEVILLE AM. (1983). HUMAN-BREAST CARCINOMA DETECTION USING A RADIOLABELED MONOCLONAL-ANTIBODY. BRIT J CANCER. 47:559-559.
• OTT RJ; RAINSBURY RM; KALIRAI T; GREY L; WESTWOOD JH; COOMBES RC; NEVILLE AM; MCCREADY VR. (1983). LOCALIZATION OF HUMAN-BREAST CARCINOMA USING A RADIOISOTOPE LABELED MONOCLONAL-ANTIBODY. BRIT J RADIOL. 56:990-991.
• COOMBES RC; COSTES JP; FENTON DE. (1983). METAL-COMPLEXES OF SYMMETRIC AND NON-SYMMETRIC TETRADENTATE SCHIFF-BASES DERIVED FROM 1-(2-MERCAPTOPHENYL)-ETHANONE. INORG CHIM A-LETT. 77:L173-L174.
• Neville AM; Foster C; Redding H; Coombes RC. (1983). Monoclonal antibodies as probes of human breast disorders. Ann N Y Acad Sci. 417:251-261.
• COOMBES RC; FENTON DE. (1983). ON THE SYNTHESIS OF 2-METHYLCHROMENE-4-THIONE AND 2-METHYL-1-THIOCHROMONE. PHOSPHORUS SULFUR. 14:139-142.
• RAINSBURY RM; COOMBES RC; WESTWOOD JH; NEVILLE AM. (1983). RADIOLABELED ANTIBODY FOR LOCALIZING METASTASES - REPLY. LANCET. 2:1368-1369.
• BUCKMAN R; MCILHINNEY RAJ; SHEPHERD V; COOMBES RC; NEVILLE AM. (1983). THE ELIMINATION OF CARCINOMA-CELLS FROM HUMAN-BONE MARROW. BRIT J CANCER. 47:558-558.
• Buckman R; McIlhinney RA; Shepherd V; Patel S; Coombes RC; Neville AM. (25 Dec 1982). Elimination of carcinoma cells from human bone marrow. Lancet. 2:1428-1430.
• Coombes RC; Foster AB; Harland SJ; Jarman M; Nice EC. (Sep 1982). Polymorphically acetylated aminoglutethimide in humans. Br J Cancer. 46:340-345.
• Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; et alZava D; Powles TJ. (Aug 1982). Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. Cancer Res. 42:3415s-3419s.
• Powles TJ; Gordon C; Coombes RC. (Aug 1982). Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res. 42:3458s-3460s.
• Coombes RC; Dearnaley DP; Ellison ML; Neville AM. (Jul 1982). Markers in breast and lung cancer. Ann Clin Biochem. 19 (Pt 4):263-268.
• Coombes RC; Powles TJ; Rees LH; Ratcliffe WA; Nash AG; Henk M; Ford HT; Gazet JC; et alNeville AM. (Jul 1982). Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer. Br J Cancer. 46:30-34.
• Williams JC; Gusterson BA; Coombes RC. (Apr 1982). Spontaneously metastasizing variants derived from MNU-induced rat mammary tumour. Br J Cancer. 45:588-597.
• Rowland-Payne CM; Abbott M; Jones JM; Powles TJ; Coombes RC. (Mar 1982). Weight loss during therapy for advanced breast cancer. Clin Oncol. 8:33-38.
• BUCKMAN R; DEARNALEY DP; ORMEROD MG; NEVILLE AM; COOMBES RC. (1982). A TECHNIQUE FOR DETECTING SMALL NUMBERS OF BREAST-CANCER CELLS IN BONE-MARROW. P AM ASSOC CANC RES. 23:152-152.
• COOMBES RC; CHILVERS C; DOWSETT M; GAZET JC; FORD HT; BETTELHEIM R; GORDON C; SMITH IE; et alZAVA D; POWLES TJ. (1982). ADJUVANT AMINOGLUTETHIMIDE THERAPY FOR POST-MENOPAUSAL PATIENTS WITH PRIMARY BREAST-CANCER - PROGRESS REPORT. CANCER RES. 42:3415-3419.
• SCHEIN PS; COOMBES RC. (1982). ADJUVANT THERAPY OF GASTROINTESTINAL CANCER. DRUG EXP CLIN RES. 8:427-433.
• POWLES TJ; GORDON C; COOMBES RC. (1982). CLINICAL-TRIAL OF MULTIPLE ENDOCRINE THERAPY FOR METASTATIC AND LOCALLY ADVANCED BREAST-CANCER WITH "TAMOXIFEN-AMINOGLUTETHIMIDE-DANAZOL COMPARED TO TAMOXIFEN USED ALONE. CANCER RES. 42:3458-3460.
• Coombes RC; Dearnaley DP; Buckman R; Jones JM; Ormerod MG; Sloane JP; Powles TJ; Gazet JC; et alFord HT; Neville AM. (1982). Detection of bone metastases in patients with breast cancer. Invasion Metastasis. 2:177-184.
• Taylor RE; Powles TJ; Humphreys J; Bettelheim R; Dowsett M; Casey AJ; Neville AM; Coombes RC. (Jan 1982). Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer. 45:80-85.
• COOMBES RC. (1982). MALIGNANCY - METABOLIC MANIFESTATIONS OF CANCER. BRIT J HOSP MED. 27:21-&.
• Coombes RC. (Jan 1982). Malignancy. Metabolic manifestations of cancer. Br J Hosp Med. 27:21-27.
• COOMBES RC; DEARNALEY DP; ELLISON ML; NEVILLE AM. (1982). MARKERS IN BREAST AND LUNG-CANCER. ANN CLIN BIOCHEM. 19:263-268.
• POWLES TJ; COOMBES RC; GORDON C; SMITH IE. (1982). VINDESINE IN COMBINATION WITH ADRIAMYCIN FOR TREATMENT OF METASTATIC BREAST-CANCER. DRUG EXP CLIN RES. 8:571-575.
• Kessel DH; Chou TH; Coombes RC. (Sep 1981). Studies on sialyltransferase isoenzymes in plasma of patients with breast cancer. Eur J Cancer Clin Oncol. 17:1035-1040.
• Coombes RC; Powles TJ; Gazet JC; Ford HT; McKinna A; Abbott M; Gehrke CW; Keyser JW; et alMitchell PE; Patel S; Stimson WH; Worwood M; Jones M; Neville AM. (15 Jul 1981). Screening for metastases in breast cancer: an assessment of biochemical and physical methods. Cancer. 48:310-315.
• Dearnaley DP; Sloane JP; Ormerod MG; Steele K; Coombes RC; Clink HM; Powles TJ; Ford HT; et alGazet JC; Neville AM. (Jul 1981). Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer. 44:85-90.
• Dearnaley DP; Kingsley DP; Husband JE; Horwich A; Coombes RC. (Jul 1981). The role of computed tomography of the brain in the investigation of breast cancer patients with suspected intracranial metastases. Clin Radiol. 32:375-382.
• Dearnaley DP; Coombes RC. (Jun 1981). Tumour markers. Their role in clinical medicine. Practitioner. 225:839-849.
• Harris AL; Smith IE; Dowsett M; Jeffcoate SL; Coombes RC; Powles TJ; Neville AM. (31 Jan 1981). Sex hormone binding globulin levels and prognosis in early breast cancer. Lancet. 1:279.
• COOMBES RC; WILLIAMS J; GUSTERSON B; HUMPHREYS J; NEVILLE AM. (1981). ARE RAT MAMMARY-TUMORS SUITABLE MODELS FOR HUMAN-BREAST CANCER. J PATHOL. 134:320-321.
• Dearnaley DP; Patel S; Powles TJ; Coombes RC. (1981). Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer. Oncodev Biol Med. 2:305-311.
• COOMBES RC; FOSTER AB; JARMAN M; RATCLIFFE W; ROWLANDS MG. (1981). DANAZOL-AROMATASE INHIBITORY PROPERTIES. BRIT J PHARMACOL. 74:P777-P778.
• DEARNALEY DP; SLOANE JP; ORMEROD MG; STEELE K; COOMBES RC; NEVILLE AM. (1981). DETECTION OF MAMMARY-CARCINOMA CELLS IN MARROW USING ANTISERA TO EPITHELIAL-MEMBRANE ANTIGEN. BRIT J CANCER. 43:727-727.
• HARLAND SJ; COOMBES RC; JARMAN M; NICE EC; FOSTER AB. (1981). IS THERE POLYMORPHIC METABOLISM OF AMINOGLUTETHIMIDE IN MAN. BRIT J CANCER. 43:719-719.
• COOMBES RC; FENTON DE; VIGATO PA; CASELLATO U; VIDALI M. (1981). MONOBINUCLEAR AND HOMOBINUCLEAR DIOXOURANIUM(VI) COMPLEXES OF VARIOUS COMPARTMENTAL LIGANDS. INORG CHIM A-LETT. 54:L155-L157.
• Williams JC; Gusterson B; Humphreys J; Monaghan P; Coombes RC; Rudland P; Neville AM. (Jan 1981). N-methyl-N-nitrosourea-induced rat mammary tumors. Hormone responsiveness but lack of spontaneous metastasis. J Natl Cancer Inst. 66:147-155.
• WILLIAMS JC; GUSTERSON BA; COOMBES RC. (1981). SELECTION OF METASTATIC VARIANTS FROM N-METHYL-N-NITROSOUREA-INDUCED RAT MAMMARY-TUMORS. BRIT J CANCER. 44:293-293.
• BUCKMAN R; DEARNALEY DP; COOMBES RC; NEVILLE AM. (1981). SEPARATION OF HUMAN BREAST-CANCER CELLS. BRIT J CANCER. 44:299-299.
• HARRIS AL; SMITH IE; DOWSETT M; JEFFCOATE SL; COOMBES RC; POWLES TJ; NEVILLE AM. (1981). SEX-HORMONE BINDING GLOBULIN LEVELS AND PROGNOSIS IN EARLY BREAST-CANCER. LANCET. 1:279-279.
• COOMBES RC. (1981). TUMOR-MARKERS - THEIR ROLE IN CLINICAL CANCER MANAGEMENT. J CLIN CHEM CLIN BIO. 19:216-216.
• DEARNALEY DP; COOMBES RC. (1981). TUMOR-MARKERS - THEIR ROLE IN CLINICAL MEDICINE. PRACTITIONER. 225:839-&.
• Coombes RC; Dearnaley D; Humphreys J; Gazet JC; Ford HT; Nash AG; Mashiter K; Powles TJ. (Oct 1980). Danazol treatment of advanced breast cancer. Cancer Treat Rep. 64:1073-1076.
• Bowen M; Ward AM; Humphreys J; Coombes RC. (Oct 1980). Sex hormone binding globulin in breast cancer. Ric Clin Lab. 10:591-595.
• Smith IE; Hedley DW; Coombes RC; Powles TJ. (Sep 1980). A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. Cancer Treat Rev. 7 Suppl 1:71-73.
• Coombes RC; Powles TJ; Abbott M; De Rivas L; Ford HT; McCready VR; Neville AM; Gazet JC. (Sep 1980). Physical test for distant metastases in patients with breast cancer. J R Soc Med. 73:617-623.
• De Rivas L; Coombes RC; McCready VR; Gazet JC; Ford HT; Neville AM; Powels TJ. (Sep 1980). Tests for liver metastases in breast cancer: evaluation of liver scan and liver ultrasound. Clin Oncol. 6:225-230.
• Sloane JP; Ormerod MG; Imrie SF; Coombes RC. (Sep 1980). The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer. 42:392-398.
• Powles TJ; Coombes RC; Smith IE; Jones JM; Ford HT; Gazet JC. (15 Mar 1980). Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1:580-582.
• Coombes RC; Powles TJ; Gazet JC; Nash AG; Ford HT; McKinna A; Neville AM. (9 Feb 1980). Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet. 1:296-297.
• SMITH IE; HEDLEY DW; COOMBES RC; POWLES TJ. (1980). A COMPARISON OF COMBINATION CHEMOTHERAPY USING VINDESINE OR VINCRISTINE WITH ADRIAMYCIN IN THE TREATMENT OF ADVANCED BREAST-CARCINOMA. CANCER TREAT REV. 7:71-73.
• COOMBES RC; JARMAN M; HARLAND S; RATCLIFFE WA; POWLES TJ; TAYLOR GN; OHARE M; NICE E; et alFOSTER AB; NEVILLE AM. (1980). AMINOGLUTETHIMIDE - METABOLISM AND EFFECTS ON STEROID-SYNTHESIS INVIVO. J ENDOCRINOL. 87:P31-P32.
• Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer C; Jones M; McKinna JA; Powles TJ. (1980). Aminoglutethimide in the management of advanced breast cancer. Eur J Cancer. Suppl 1:99-101.
• COOMBES RC; GAZET JC; FORD HT; POWLES TJ; NASH AG; MCKINNA A. (1980). ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST-CANCER. LANCET. 1:296-298.
• DEARNALEY DP; PATEL S; POWLES TJ; COOMBES RC. (1980). CAE ESTIMATION IN CEREBROSPINAL-FLUID IN PATIENTS WITH METASTATIC BREAST-CANCER. BRIT J CANCER. 42:199-200.
• WILLIAMS JC; COOMBES RC; GUSTERSON BA. (1980). CHARACTERISTICS OF N-NITROSOMETHYLUREA-INDUCED MAMMARY-TUMORS IN THE RAT. BRIT J CANCER. 42:194-195.
• Grudzinskas JG; Coombes RC; Ratcliffe JG; Gordon YB; Powles TJ; Neville AM; Chard T. (1 Jan 1980). Circulating levels of pregnancy specific beta 1 glycopretein in patients with testicular, bronchogenic and breast carcinomas. Cancer. 45:102-103.
• ORMEROD MG; SLOANE JP; IMRIE SF; STEELE K; COOMBES RC; NEVILLE AM. (1980). DETECTION OF MICRO-METASTESES OF MAMMARY-CARCINOMA USING AN IMMUNOHISTOCHEMICAL STAIN FOR EPITHELIAL MEMBRANE ANTIGEN (EMA). BRIT J CANCER. 42:183-184.
• SLOANE J; ORMEROD MG; IMRIE S; COOMBES RC. (1980). EPITHELIAL MEMBRANE ANTIGEN AND BREAST-CANCER. BRIT J RADIOL. 53:1115-1115.
• HUMPHREYS J; WESTWOOD JH; ORMEROD MG; COOMBES RC; NEVILLE AM. (1980). IMMUNO-CYTOCHEMICAL LOCALIZATION OF ESTROGEN-RECEPTORS. BRIT J CANCER. 42:183-183.
• COOMBES RC; DADY P; PARSONS C; POWLES TJ. (1980). MITHRAMYCIN THERAPY - AN ADJUNCT TO CONVENTIONAL TREATMENT OF HYPERCALCEMIA AND BONE METASTASES IN BREAST-CANCER. METAB BONE DIS RELAT. 2:199-202.
• Coombes RC; Powles TJ; Ford HT; Gazet JC; Gehrke CW; Keyser JW; Mitchell PE; Patel S; et alStimson WH; Abbott M; Worwood M; Neville AM. (1980). The value of sequential marker estimations following mastectomy for breast cancer. Eur J Cancer. Suppl 1:25-30.
• COOMBES RC. (1980). THE VALUE OF SEQUENTIAL MARKER ESTIMATIONS FOLLOWING MASTECTOMY FOR BREAST-CANCER AND COMPARISON WITH PHYSICAL STAGING TECHNIQUES. BRIT J RADIOL. 53:1115-1115.
• Dady PJ; Coombes RC; Smith IE; Parsons CA; Ford HT; Gazet JC; Henk JM; Nash AG; et alPowles TJ. (1980). Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer. Eur J Cancer. Suppl 1:131-135.
• Powles TJ; Dady PJ; Williams J; Easty GC; Coombes RC. (1980). Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res. 6:511-516.
• Smith IE; Coombes RC; Evans BD; Ford HT; Gazet JC; Gordon C; McKinna JA; Powles TJ. (1980). Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma. Eur J Cancer. Suppl 1:271-273.
• Coombes RC; Neville AM; Gazet JC; Ford HT; Nash AG; Baker JW; Powles JT. (1979). Agents affecting osteolysis in patients with breast cancer. Cancer Chemother Pharmacol. 3:41-44.
• Coombes RC; Powles TJ; Gehrke CW; Waalkes TP; Neville AM. (Jan 1979). Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances. Invest Cell Pathol. 2:11-14.
• Coombes RC; Ellison ML; Neville AM. (Oct 1978). Biochemical markers in bronchogenic carcinoma. Br J Dis Chest. 72:263-287.
• Neville AM; Patel S; Capp M; Laurence DJ; Cooper EH; Turberville C; Coombes RC. (Sep 1978). The monitoring role of plasma CEA alone and in association with other tumor markers in colorectal and mammary carcinoma. Cancer. 42:1448-1451.
• Thomas JM; Redding WH; Coombes RC; Sloane JP; Ford HT; Gazet JC; Powles TJ. (15 Jul 1978). Failure to detect intra-abdominal metastases from breast cancer: a case for staging laparotomy. Br Med J. 2:157-159.
• COOMBES RC. (1978). BIOCHEMICAL MARKERS IN HUMAN BREAST CARCINOMA. INVEST CELL PATHOL. 1:347-362.
• Coombes RC; Powles TJ; Neville AM. (Dec 1977). Evaluation of biochemical markers in breast cancer. Proc R Soc Med. 70:843-845.
• Coombes RC; Powles TJ; Gazet JC; Ford HT; Nash AG; Sloane JP; Hillyard CJ; Thomas P; et alKeyser JW; Marcus D; Zinberg N; Stimson WH; Neville AM. (Aug 1977). A biochemical approach to the staging of human breast cancer. Cancer. 40:937-944.
• Powles TJ; Coombes RC; Neville AM; Ford HT; Gazet JC; Levine L. (16 Jul 1977). 15-keto-13,14-dihydroprostaglandin E2 concentrations in serum of patients with breast cancer. Lancet. 2:138.
• Himsworth RL; Bloomfield GA; Coombes RC; Ellison M; Gilkes JJ; Lowry PJ; Setchell KD; Slavin G; et alRees LH. (Jul 1977). 'Big ACTH' and calcitonin in an ectopic hormone secreting tumour of the liver. Clin Endocrinol (Oxf). 7:45-62.
• Hillyard CJ; Cooke TJ; Coombes RC; Evans IM; Macintyre I. (Apr 1977). Normal plasma calcitonin: circadian variation and response to stimuli. Clin Endocrinol (Oxf). 6:291-298.
• Coombes RC; Powles TJ; Joplin DG. (Mar 1977). Calcium metabolism in breast cancer. Proc R Soc Med. 70:195-199.
• Coombes RC; Powles TJ; Gazet JC; Ford HT; Sloane JP; Laurence DJ; Neville AM. (15 Jan 1977). Biochemical markers in human breast cancer. Lancet. 1:132-134.
• POWLES TJ; COOMBES RC; NEVILLE AM; FORD HT; GAZET JC; LEVINE L. (1977). 15-KETO-13,14-DIHYDROPROSTAGLANDIN-E2 CONCENTRATIONS IN SERUM OF PATIENTS WITH BREAST-CANCER. LANCET. 2:138-138.
• Coombes RC; Neville AM; Bondy PK; Powles TJ. (Dec 1976). Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. Prostaglandins. 12:1027-1035.
• Hillyard CJ; Coombes RC; Greenberg PB; MacIntyre I. (Aug 1976). Immunoreactive calcitonin in non-thyroid tumours. Calcif Tissue Res. 21 Suppl:304-309.
• Hillyard CJ; Coombes RC; Greenberg PB; Galante LS; MacIntyre I. (Jan 1976). Calcitonin in breast and lung cancer. Clin Endocrinol (Oxf). 5:1-8.
• HILLYARD CJ; COOKE TJC; COOMBES RC; EVANS IMA; MACINTYRE I. (1976). CALCITONIN IN NORMAL SUBJECTS - DIURNAL-VARIATION AND RESPONSE TO ORAL WHISKY AND CALCIUM INFUSION. J ENDOCRINOL. 71:P85-P86.
• COOMBES RC; WARD MK; GREENBERG PB; HILLYARD CJ; TULLOCH BR; MORRISON R; JOPLIN GF. (1976). CALCIUM-METABOLISM IN CANCER - STUDIES USING CALCIUM ISOTOPES AND IMMUNOASSAYS FOR PARATHYROID-HORMONE AND CALCITONIN. CANCER. 38:2111-2120.
• ELLISON M; HILLYARD CJ; COOMBES RC; NEVILLE AM. (1976). CONTROL OF CALCITONIN RELEASE INVITRO. J ENDOCRINOL. 71:P85-P85.
• ELLISON ML; HILLYARD CJ; BLOOMFIELD GA; REES LH; COOMBES RC; NEVILLE AM. (1976). ECTOPIC HORMONE PRODUCTION BY BRONCHIAL CARCINOMAS IN CULTURE. CLIN ENDOCRINOL. 5:S397-S406.
• Ellison ML; Hillyard CJ; Bloomfield GA; Rees LH; Coombes RC; Neville AM. (1976). Ectopic hormone production by bronchial carcinomas in culture. Clin Endocrinol (Oxf). 5 Suppl:397S-406S.
• COOMBES RC; ELLISON ML; EASTY GC; HILLYARD CJ; JAMES R; GALANTE L; GIRGIS S; HEYWOOD L; et alMACINTYRE I; NEVILLE AM. (1976). ECTOPIC SECRETION OF CALCITONIN BY LUNG AND BREAST CARCINOMAS. CLIN ENDOCRINOL. 5:S387-S396.
• COOMBES RC; NEVILLE AM; BONDY PK; POWLES TJ. (1976). FAILURE OF INDOMETHACIN TO REDUCE HYDROXYPROLINE EXCRETION OR HYPERCALCEMIA IN PATIENTS WITH BREAST-CANCER. PROSTAGLANDINS. 12:1027-1035.
• HILLYARD CJ; COOMBES RC; GREENBERG PB; MACINTYRE I. (1976). IMMUNOREACTIVE CALCITONIN IN NON-THYROID TUMORS. CALC TISS RES. 21:304-309.
• COOMBES RC; HILLYARD CJ; POWLES TJ; MACINTYRE I; NEVILLE AM. (1976). RESPONSE OF CIRCULATING IMMUNOREACTIVE CALCITONIN TO SECRETOGOGS IN PATIENTS WITH BREAST-CANCER. EUR J CLIN INVEST. 6:319-319.
• Coombes RC; Ellison ML; Easty GC; Hillyard CJ; James R; Galante L; Girgis S; Heywood L; et alMacIntyre I; Neville AM. (1976). The ectopic secretion of calcitonin by lung and breast carcinomas. Clin Endocrinol (Oxf). 5 Suppl:387S-396S.
• Coombes RC; Easty GC; Detre SI; Hillyard CJ; Stevens U; Girgis SI; Galante LS; Heywood L; et alMacintyre I; Neville AM. (25 Oct 1975). Secretion of immunoreactive calcitonin by human breast carcinomas. Br Med J. 4:197-199.
• Ellison M; Woodhouse D; Hillyard C; Dowsett M; Coombes RC; Gilby ED; Greenberg PB; Neville AM. (Sep 1975). Immunoreactive calcitonin production by human lung carcinoma cells in culture. Br J Cancer. 32:373-379.
• Hillyard CJ; Coombes RC; Greenberg PB; MacIntyre I. (Jul 1975). Proceedings: Immunoreactive calcitonin in patients with carcinomata. J Endocrinol. 66:2P-3P.
• HILLYARD CJ; COOMBES RC; GREENBERG PB; MACINTYRE I. (1975). IMMUNOREACTIVE CALCITONIN IN PATIENTS WITH CARCINOMATA. J ENDOCRINOL. 66:P2-P3.
• Coombes RC; Hillyard C; Greenberg PB; MacIntyre I. (1 Jun 1974). Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet. 1:1080-1083.
• COOMBES RC; HILLYARD C; GREENBER.PB; MACINTYR.I. (1974). PLASMA-CALCITONIN AND NON-THYROID TUMORS - REPLY. LANCET. 2:164-164.

Conferences

• Giamas G; Filipovic A; Messier W; Lenz H; Stebbing J. Kinome Screening for Regulators of Estrogen Receptor Identifies a Novel Kinase as a New Therapeutic Target in Breast Cancer. 33th Annual CTRC-AACR San Antonio Breast Cancer Symposium, 8 Dec 2010 - 12 Dec 2010. Publisher weblink.
• Kenny LM; Coombes RC; Contractor K; Stebbing J; Al-Nahhas A; Palmieri C; Shousha S; Lowdell C; et alAboagye E. [11C]Choline-PET imaging of breast cancer. 27. (20 May 2009).
• Gordon AB; Stebbing J; Shousha MS; Coombes RC. Tumor Volume Analysis and Tumor Doubling. 69:774S-775S. (15 Dec 2009).
• Kenny LM; Contractor K; Stebbing J; Al-Nahhas A; Palmieri C; Shousha S; Aboagye EO; Coombes RC. Changes in [F-18]Fluorothymidine Pharmacokinetics Following Capecitabine Treatment in Human Breast Cancer Detected by Positron Emission Tomography. 69:765S-765S. (15 Dec 2009).
• Coombes RC; Schmid P; Isambert N; Soulie P; Cardoso F; Besse-Hammer T; Lesimple T; Slosman DO; et alKornowski AH; Fohanno VM; Fumoleau P. A Phase I Dose Escalation Study of Steroid Sulfatase Inhibitor BN83495/STX64 in Postmenopausal Women with ER Positive Breast Cancer. 69:739S-739S. (15 Dec 2009).
• Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; et alAndersen J; Paridaens RJ; Coombes RC; IES Steering Comm. Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES). 69:487S-487S. (15 Dec 2009).
• Filipovic A; Rashied S; Balasubramanian R; Shao D; Yague E; Coombes RC. Inhibiting nicastrin (NCT) stabilizes expression of e-cadherin and has potential in inducing mesenchymal to epithelial transition in breast cancer (BC). 69:224S-224S. (15 Jan 2009).
• LONNING PE. AROMATASE INHIBITORS - FUTURE-PROSPECTS. 180:55-59. (1991).
• STEIN R. INITIAL STUDIES WITH 4-HYDROXYANDROSTENEDIONE IN PREMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER. 180:35-39. (1991).
• JONES AL. INHIBITION OF PERIPHERAL AROMATIZATION BY 4-HYDROXYANDROSTENEDIONE - RADIOACTIVE-TRACER STUDIES INVIVO. 180:29-33. (1991).
• BAKER JRJ. PHASE-II CLINICAL-TRIALS WITH 4-HYDROXYANDROSTENEDIONE - PRELIMINARY-REPORT. 180:25-27. (1991).
• COOMBES RC. CLINICAL-STUDIES WITH 4-HYDROXYANDROSTENEDIONE IN ADVANCED BREAST-CANCER. 180:19-23. (1991).
• JARMAN M. PHARMACOKINETIC AND METABOLIC STUDIES WITH 4-HYDROXYANDROSTENEDIONE. 180:13-18. (1991).
• MILLER WR. INVITRO AND INVIVO EFFECTS OF 4-HYDROXY-ANDROSTENEDIONE ON STEROID AND TUMOR METABOLISM. 180:45-49. (1991).
• COLSTON KW; MACKAY AG; CHANDER S; BINDERUP L; COOMBES RC. NOVEL VITAMIN-D ANALOGS SUPPRESS TUMOR-GROWTH INVIVO. 465-466. (1991).
• DISALLE E; ORNATI G; PARIDAENS R; COOMBES RC; LOBELLE JP; ZURLO MG. PRECLINICAL AND CLINICAL PHARMACOLOGY OF THE AROMATASE INHIBITOR EXEMESTANE (FCE-24304). 1064:303-310. (1994).
• Coombes RC. What is the optimal hormonal treatment in pre- and post-menopausal patients?. 11-16. (1996).
• Schoenfeld A; Kruger KH; Gomm J; Sinnett HD; Gazet JC; Sacks N; Bender HG; Luqmani Y; et alCoombes RC. The detection of micrometastases in the lymph nodes, peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and the polymerase chain reaction. 289-302. (1996).
• Page K; Hava N; Slade MJ; Walker RA; Coombes RC; Shaw JA. Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR - art. no. P70. Breast Cancer Research Meeting. 10:S36-S36. (Feb 2008).
• Buzdar AU; Coombes RC; Goss PE; Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. 6th Cambridge Conference on Endocrine and Targeted Manipulation of Breast Cancer. 112:700-709. (1 Feb 2008).
• Come SE; Buzdar AU; Ingle JN; Johnston SRD; Brodie AM; Coombes RC; Miller WR; Pritchard KI; et alWiner EP; Zujewski JA; Goss PE. Endocrine and Targeted Manipulation of Breast Cancer: Summary statement for the Sixth Cambridge Conference. 6th Cambridge Conference on Endocrine and Targeted Manipulation of Breast Cancer. 112:673-678. (1 Feb 2008).
• Bertelli G; Hall E; Ireland E; Jassem J; Bliss JM; Snowdon CF; Coombes RC; IES Grp. Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment. 30th Annual San Antonio Breast Cancer Symposium. 106:S111-S111. (Dec 2007).
• Zaidi A; Tripuraneni G; Weller S; Ward B; Sinnett HD; Coombes RC; Slade MJ. Minimal residue disease (MRD) - art. no. P18. 7th Madrid Breat Cancer Conference. 9:P18-P18. (Jan 2007).
• Zaidi A; Tripuraneni G; Weller S; Ward B; Sinnett HD; Coombes RC; Slade MJ. Minimal residue disease (MRD). 9. (2007). DOI.
• COOMBES RC; STEIN RC. NEW ASPECTS OF THE DIAGNOSIS AND TREATMENT OF BREAST-CANCER. CONSENSUS DEVELOPMENT CONF ON THERAPEUTIC MANAGEMENT OF METASTATIC BREAST CANCER. 1:33-50. (1989).
• REED MJ. EFFECT OF TREATMENT WITH 4-HYDROXYANDROSTENEDIONE ON AROMATASE-ACTIVITY IN NORMAL AND MALIGNANT BREAST-TISSUE. MEETING ON 4-HYDROXYANDROSTENEDIONE - A NEW APPROACH TO HORMON-DEPENDENT CANCER. 180:51-54. (1991).
• SHEARER R; DAVIES JH. STUDIES IN PROSTATIC-CANCER WITH 4-HYDROXYANDROSTENEDIONE. MEETING ON 4-HYDROXYANDROSTENEDIONE - A NEW APPROACH TO HORMON-DEPENDENT CANCER. 180:41-44. (1991).
• DOWSETT M. ENDOCRINE STUDIES WITH 4-HYDROXYANDROSTENEDIONE. MEETING ON 4-HYDROXYANDROSTENEDIONE - A NEW APPROACH TO HORMON-DEPENDENT CANCER. 180:7-12. (1991).
• BRODIE AMH. INTRODUCTION TO 4-HYDROXYANDROSTENEDIONE (4-OHA). MEETING ON 4-HYDROXYANDROSTENEDIONE - A NEW APPROACH TO HORMON-DEPENDENT CANCER. 180:1-6. (1991).
• BOWER M; COLSTON KW; HEDLEY A; STEIN R; COOMBES RC. TOPICAL VITAMIN-D ANALOGS IN ADVANCED BREAST-CANCER. 8TH WORKSHOP ON VITAMIN D. 461-462. (1991).
• SAHOTA SS; EDGAR AJ; COLSTON KW; COOMBES RC. ANALYSIS OF 1,25 DIHYDROXYVITAMIN-D3 MESSENGER-RNA IN HUMAN BREAST-CANCER TISSUES BY POLYMERASE CHAIN-REACTION AND IN RAT MAMMARY-TUMORS BY NORTHERN BLOTS. 8TH WORKSHOP ON VITAMIN D. 459-460. (1991).
• COOMBES RC. Node negative breast cancer. Eurocancer 1994. 42:958-958. (Dec 1994).
• Hu JCC; Han Z; Liu B; Robinson M; Branston R; Coombes RC; Coffin RS. Combination of OncoVEX with chemotherapy for cancer treatment. 11th International Conference on Gene Therapy of Cancer. 10:S24-S24. (Jan 2003).
• Mouridsen H; Van der Burg S; Kamby C; Melief CJM; Coombes RC; Ewertz M; O'Byrne K; Cold S; et alVolck B. The short-term safety and immune responses of HER-2 DNA AutoVac (TM) (ME 103.1.1) in patients with HER-2 positive metastatic breast cancer. Results from the first dose level of the Phase I multi-dose trial. 25th San Antonio Breast Cancer Symposium. 76:S80-S80. (Dec 2002).
• Braun S; Vogl FD; Schlimok G; Diel IJ; Janni W; Gerber B; Gebauer G; Coombes RC; et alPierga JY; Naume B; Pantel K; Collaborative Grp Bone Marrow Micr. Pooled analysis of prognostic impact of bone marrow micrometastasis: 10-year survival of 4199 breast cancer patients. 26th Annual San Antonio Breast Cancer Symposium. 82:S8-S8. (Jan 2003).
• Kenny LM; Al-Nahhas A; Vigushin D; Coombes RC; Aboagye EO. [F-18]Fluorothymidine retention in breast cancer measured by PET - Initial results from a pilot study. Annual Congress of the European-Association-of-Nuclear-Medicine. 31:S328-S328. (Aug 2004).
• Marty ME; Coombes RC; Peckitt C; Lopez FRP; Tres A; Morvan F; Tubiana-Mathieu N; Espie M; et alBliss JM; Intl Collaborative Canc Grp. Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer. 40th Annual Meeting of the American-Society-of-Clinical-Oncology. 22:25S-25S. (15 Jul 2004).
• Fallowfield LJ; Price MH; Hall E; Coombes RC; Bliss JM. Intergroup exemestane study: results of the quality of life sub-protocol. 27th Annual Charles A Colman San Antonio Breast Cancer Symposium. 88:S8-S8. (Jan 2004).
• Stanway S; Purohit A; Woo LW; Wilson R; Sufi S; Dobbs N; Vigushin D; Stanczyk FZ; et alPotter BV; Reed MJ; Coombes RC. Inhibition of steroid sulfatase by 667 COUMATE (STX64): a new treatment paradigm for breast cancer. 28th Annual San Antonio Breast Cancer Symposium. 94:S233-S233. (Jan 2005).
• Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Porter LS; Snowdon CF; Hall E; et alBliss JM; Coombes RC; IES. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. 28th Annual San Antonio Breast Cancer Symposium. 94:S233-S233. (Jan 2005).
• Coombes RC; Paridaens R; Jassem J; Van de Velde CJ; Delozier T; Jones SE; Hall E; Kilburn LS; et alSnowdon CF; Bliss JM; IES. First mature analysis of the Intergroup Exemestane Study. 42nd Annual Meeting of the American-Society-of-Clinical-Oncology. 24:933S-933S. (20 Jun 2006).
• Kenny LM; Coombes RC; Al-Nahhas A; Osman S; Lowdell C; Aboagye E. A feasibility study of [C-11]choline for the molecular imaging of human breast cancer in vivo using positron emission tomography (PET). 42nd Annual Meeting of the American-Society-of-Clinical-Oncology. 24:31S-31S. (20 Jun 2006).
• Stanway S; Purohit A; Woo LW; Wilson RH; Stanczyk FZ; Dobbs N; Delavault P; Potter BV; et alReed MJ; Coombes RC. Endocrine and clinical responses to steroid sulfatase inhibition: Results from the first phase I trial in women with breast cancer. 42nd Annual Meeting of the American-Society-of-Clinical-Oncology. 24:22S-22S. (20 Jun 2006).
• Abbott R; Vigushin DM; Coombes RC; Palmieri C. Angiosarcoma of the breast following breast preserving surgery and radiotherapy: A review of the literature. 29th Annual San Antonio Breast Cancer Symposium. 100:S235-S235. (Jan 2006).
• Kenny LM; Aboagye EO; Al-Nahhas A; Charles L; Coombes RC. [C-11]choline-PET in human breast cancer: utility, reproducibility and effect of receptor tyrosine kinase inhibition by trastuzumab. 29th Annual San Antonio Breast Cancer Symposium. 100:S212-S212. (Jan 2006).
• Jassem J; Coombes RC; Ireland B; Hall E; Snowdon CF; Bliss JM. Approaches to postmastectomy radiotherapy (PMRT) in the intergroup exemestane study (IES). 81:S278-S278. (Oct 2006).
• Slade MJ; Tamburo DeBella M; Zaidi A; Payne R; Ward B; Sinnett HD; Coombes RC. GATA-3: a potential marker of micrometastases in the bone marrow in primary breast cancer patients. 100:S217-S217. (2006).
• Slade MJ; Zaidi A; Payne R; Tripuraneni G; Ward B; Sinnett HD; Coombes RC. Persistence of bone marrow micrometastases in primary breast cancer patients: high dose versus standard chemotherapy versus endocrine regime. Results at 3.5 years. 100:S216-S216. (2006).
• Stanway SJ; Purohit A; Woo LLW; Stanczyk FZ; Potter BVL; Folkherd EJ; Dowsett M; Coombes RC; et alReed MJ. The effects of an aromatase inhibitor (anastrozole) or sulfatase inhibitor (STX64) on androgen concentrations in postmenopausal women with breast cancer. 100:S189-S189. (2006).
• Bliss JM; Kilburn L; Ireland B; Snowdon CF; Coombes RC; Intergroup Exemestane Study. Tamoxifen washout - the effect on safety in the intergroup exemestane study (IES). 100:S187-S187. (2006).
• Sarwar N; Jiang J; Shousha S; Coombes RC; Ali S. Investigation of estrogen receptor phosphorylation in breast cancer. 100:S163-S163. (2006).
• Ali S; Sarwar N; Jiang J; Peston D; Sinnett HD; Madden P; Shousha S; Lykkesfeldt AE; et alGee JM; Nicholson RI; Kulinskaya E; Coombes RC. Immunohistochemical determination of estrogen receptor-alpha phosphorylation in activation function AF1 in primary and tamoxifen-resistant breast cancer is indicative of a complex role for estrogen receptor-alpha phosphorylation in breast cancer progression. 100:S36-S37. (2006).
• Coombes RC; Paridaens R; Jassem J; Van de Velde CJ; Delozier T; Jones SE; Hall E; Kilburn LS; et alSnowdon CF; Bliss JM; Intergroup Exemestane Study. First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. 24:9S-9S. (20 Jun 2006).
• Gillmore R; Xue S; Holler A; Kaeda J; Hadjiminas D; Healy V; Ghani Y; Coombes RC; et alWaxman J; Stauss HJ. Cytotoxic T cells specific for the Wilms' tumor protein are present in patients with breast cancer and are of sufficient avidity to kill breast cancer cells. 33:96-96. (Jul 2005).
• Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Ali S; Slade MJ; Shousha S; et alMorrisson K; Coombes RC. Anti-proliferative and molecular effects of neoadjuvant (pre-operative) gefitinib alone or in combination with anastrozole in epidermal growth factor receptor (EGFR) positive, estrogen receptor alpha [ER alpha) positive patients with primary breast cancer. 23:16S-16S. (1 Jun 2005).
• Kenny LM; Vigushin DM; Coombes RC; Osman S; Shousha S; Al-Nahhas A; Aboagye E. Early assessment of response to treatment in breast cancer by [F-18]fluorathymidine-positron emission tomography. 23:155S-155S. (1 Jun 2005).
• Sarwar N; Kim JS; Jiang J; Peston D; Shousha S; Coombes RC; Ali S. Phosphorylation of estrogen receptor alpha at serine 118 in human breast tumours. 23:855S-855S. (1 Jun 2005).
• Shaw JA; Dampier K; De Bella MT; Primrose L; Slade ML; Powles T; Walker RA; Coombes RC. Analysis of serial plasma DNA samples during follow up of women with primary breast cancers. 205:1-1. (Mar 2005).
• Coombes RC; De Bella MT; Tripuraneni G; Zaidi A; Anwer S; Stephens DA; Ward B; Sinnett HD; et alSlade MJ. Minimal residual disease (MRD) in the bone marrow in ER-alpha-positive primary breast cancer patients. 7:S5-S6. (2005). DOI.
• Stanway SJ; Purohit A; Woo L; Sufi S; Dobbs N; Elliott M; Potter B; Reed M; et alCoombes RC. First phase I trial of a steroid sulfatase inhibitor in breast cancer. 22:38S-38S. (15 Jul 2004).
• Kenny L; Al-Nahhas A; Shousha S; Osman S; Vigushin DM; Coombes RC; Aboagye EO. Determination of [F-18]fluorothymidine kinetics in tumour and normal tissues of patients with breast cancer using positron emission tomography. 91:S44-S44. (Jul 2004).
• Jassem J; Hall E; Bliss JM; Patel R; Snowdon CF; Coombes RC. Approaches to adjuvant chemotherapy in postmenopausal breast cancer patients in the Intergroup Exemestane Study. 88:S63-S64. (2004).
• Coleman RE; Banks LM; Hall E; Price D; Girgis S; Bliss JM; Coombes RC. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. 88:S35-S35. (2004).
• Bertelli G; Hall E; Bliss JM; Snowdon CF; Coombes RC. Intergroup Exemestane Study: results of the endometrial sub-protocol. 88:S35-S35. (2004).
• Coombes RC; Hall E; Snowdon CF; Bliss JM. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen updated survival analysis. 88:S7-S7. (2004).
• Mazhar D; Ali S; Buluwela L; Waxman J; Coombes RC. Gene ice as applied to studies of hormonally-responsive cancers. 88:S4-S4. (Jul 2003).
• Sarwar N; Chen D; Constantinidou D; Coombes RC; Ali S. Phosphorylation of estrogen receptor alpha as a potential mechanism underlying resistance to endocrine therapies. 82:S169-S169. (2003).
• Palmieri C; Lam E; Mansi J; Madden P; Warner M; Gustafsson JA; Coombes RC. The expression of ER beta cx in human breast cancer and the relationship to response to endocrine therapy and survival. 82:S62-S62. (2003).
• Singh A; De Bella MT; Kothari M; Smith C; Foxwell B; Ali S; Coombes RC. A novel functional estrogen receptor reporter gene assay (FERA) demonstrates functional differences in oestrogen receptor activity in primary and metastatic breast cancer cells. 76:S56-S56. (Dec 2002).
• Fraser SP; Diss JKJ; Mycielska ME; Coombes RC; Djamgoz MBA. Voltage-gated sodium channel expression in human breast cancer cells: possible functional role in metastasis. 76:S142-S142. (Dec 2002).
• Coombes RC; Buluwela L; Gomm JJ. The role of myoepithelial-derived growth factors in the human breast. 4:35-43. (1997).
• COOMBES RC. NODE-NEGATIVE BREAST-CANCER. 42:958-958. (Dec 1994).
• TOPHAM C; GLEES J; COOMBES RC. COMPARISON OF SINGLE-AGENT EPIRUBICIN AND 5-FLUOROURACIL EPIRUBICIN MITOMYCIN IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE PANCREAS. 50:78-83. (Apr 1993).
• DOWSETT M; MEHTA A; KING N; SMITH IE; POWLES TJ; STEIN RC; COOMBES RC. AN ENDOCRINE AND PHARMACOKINETIC STUDY OF 4 ORAL DOSES OF FORMESTANE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS. 28A:415-420. (Feb 1992).

Patents

• Nicastrin; a new target in human breast cancer. N/A. Published: 2007.
• Cdk7 inhibitors. Barrett A. Published: 2007.
• NaVChannel expression: a novel prognostic factor in breast cancer. Djamgoz M. Published: 2003.
• Functional Estrogen Receptor Assay. Ali S. Published: 1999.
• Novel anti-estrogen. Kirk D. Published: 1990.
• Use of voltage gated channels in prediciton of relapse of breast cancer data. Published: 2001.